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Abstract
Background
Early accurate detection of all skin cancer types is important to guide appropriate management and to improve morbidity and
survival. Basal cell carcinoma (BCC) is usually a localised skin cancer but with potential to infiltrate and damage surrounding
tissue, whereas squamous cell carcinoma (cSCC) and melanoma are higher risk skin cancers with the potential to
metastasise and ultimately lead to death. When used in conjunction with clinical or dermoscopic suspicion of malignancy, or
both, reflectance confocal microscopy (RCM) may help to identify those eligible for non-surgical treatment without the need
for a diagnostic biopsy, particularly in people with suspected BCC. Any potential benefit must be balanced against the risk of
any misdiagnoses.
Objectives
1) To determine the diagnostic accuracy of RCM for the detection of BCC, cSCC, or any skin cancer in adults with a) any
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suspicious lesion and b) lesions that are difficult to diagnose (equivocal); and 2) to compare its accuracy with that of usual
practice (visual inspection or dermoscopy, or both).
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; EMBASE; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies of any design that evaluated the accuracy of RCM alone, or RCM in comparison to visual inspection or dermoscopy,
or both, in adults with lesions suspicious for skin cancer compared with a reference standard of either histological
confirmation or clinical follow-up, or both.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). We contacted authors of included studies where information related to the target condition or
diagnostic threshold were missing. We estimated summary sensitivities and specificities using the bivariate hierarchical
model. For computation of likely numbers of true positive, false positive, false negative, and true negative findings in the
'Summary of findings' tables, summary sensitivity and specificity estimates were applied to lower quartile, median and upper
quartiles of the prevalence observed in the study groups. We also investigated the impact of observer experience.
Main results
Ten studies reporting on a total of 11 study cohorts were included. All 11 cohorts reported data for the detection of BCC,
including 2037 lesions (464 with BCC); and four cohorts reported data for the detection of cSCC, including 834 lesions (71
with cSCC). Only one study also reported data for the detection of BCC or cSCC using dermoscopy, limiting comparisons
between RCM and dermoscopy. Studies were at high or unclear risk of bias across almost all methodological quality
domains, and were of high or unclear concern regarding applicability of the evidence. Selective participant recruitment,
unclear blinding of the reference test, and exclusions due to image quality or technical difficulties were observed. It is unclear
whether studies are representative of populations eligible for testing with RCM, and test interpretation was often undertaken
using images, remotely from the patient and the interpreter blinded to clinical information that would normally be available in
practice.
Meta-analysis found RCM to be more sensitive but less specific for the detection of BCC in studies of participants with
equivocal lesions (sensitivity 94%, 95% CI 79% to 98%; specificity 85%, 95% CI 72% to 92%; n = 3 studies) compared to
studies that included any suspicious lesion (sensitivity 76%, 95% CI 45% to 92%; specificity 95%, 95% CI 66% to 99%; n = 4
studies), although confidence intervals were wide. At the median prevalence of disease of 12.5% observed in studies
including any suspicious lesion, applying these results to a hypothetical population of 1000 lesions results in 30 BCCs
missed with 44 false positive results (lesions misdiagnosed as BCCs). At the median prevalence of disease of 15% observed
in studies of equivocal lesions, 9 BCCs would be missed with 128 false positive results in a population of 1000 lesions.
Across both sets of studies, up to 15% of these false positive lesions were observed to be melanomas mistaken for BCCs.
There was some suggestion of higher sensitivities in studies with more experienced observers. Summary sensitivity and
specificity could not be estimated for the detection of cSCC due to paucity of data.
Authors' conclusions
There is insufficient evidence for the use of RCM for the diagnosis of BCC or cSCC in either population group. A possible
role for RCM in clinical practice is as a tool to avoid diagnostic biopsies in lesions with a relatively high clinical suspicion of
BCC. The potential for, and consequences of, misclassification of other skin cancers such as melanoma as BCCs requires
further research. Importantly, data are lacking that compare RCM to standard clinical practice (with or without dermoscopy).
Plain language summary
What is the diagnostic accuracy of reflectance confocal microscopy (RCM) for the detection of basal or
squamous cell carcinoma of the skin in adults?
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate reflectance confocal microscopy (RCM) is on its own or
compared to inspection of a skin lesion with the naked eye alone or using a hand-held microscope called dermoscopy for
diagnosing two common forms of keratinocyte skin cancer: basal cell carcinoma (BCC) or cutaneous squamous cell
carcinoma (cSCC) in adults. Researchers in Cochrane included 10 studies to answer this question.
Why is improving the diagnosis of BCC or cSCC important?
There are a number of different types of skin cancer. BCC and cSCC are usually localised skin cancers. Making the correct
diagnosis is important because mistaking one skin cancer for another can lead to the wrong treatment being used or lead to
a delay in effective treatment. A missed diagnosis of BCC (known as a false negative result) can result in the missed BCC
growing and causing disfigurement. A missed diagnosis of cSCC is more serious as it could spread to other parts of the
body. Diagnosing a skin cancer when it is not actually present (a false positive result) may result in unnecessary biopsy or
treatment and can cause discomfort and worry to patients.
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What was studied in the review?
Microscopic techniques are used by skin cancer specialists to provide a more detailed, magnified examination of suspicious
skin lesions than can be achieved using the naked eye alone. Currently, dermoscopy is used by doctors as part of the
examination of suspicious skin lesions. RCM is a new microscopic technique to increase the magnification. It is a handheld
device or static unit using infrared light that can visualise deeper layers of the skin when compared with dermoscopy. Both
techniques are painless procedures, but RCM is more expensive, time consuming, and requires additional specialised
training. Dermoscopy can be used by general practitioners whereas RCM is likely to only be used by hospital specialists for
people who have been referred with a skin lesion that is suspected to be a skin cancer. We wanted to see if RCM should be
used instead of, or as well as, inspection of a skin lesion with the naked eye alone or using dermoscopy in order to diagnose
BCC or cSCC. The accuracy of the test was looked at when used on people with any suspicious skin lesion and also in those
with skin lesions that were tricky to diagnose.
What are the main results of the review?
The review included 10 studies that included information on 11 groups of people with lesions suspicious for skin cancer. The
main results are based on 7 of the 11 sets of data: four in any lesion suspicious for skin cancer and three in particularly
difficult to diagnose skin lesions.
For the comparison of RCM versus dermoscopy, four sets of data that included 912 suspicious skin lesions were found. The
results suggest that in a group of 1000 people with any suspicious lesion, of whom 125 (12.5%) really do have BCC:
- An estimated 139 will have an RCM result indicating BCC is present.
- Of these, 44 (32%) will not have BCC (false positive results) including one person with a melanoma mistaken for a BCC.
- Of the 861 people with an RCM result indicating that BCC is not present, 30 (3%) will actually have BCC.
The review also included 3 sets of data on people that had 668 particularly difficult to diagnose skin lesions, one comparing
RCM to dermoscopy. The results suggest that if RCM was to be used by skin specialists in a group of 1000 people, of whom
150 (15%) really do have BCC:
- An estimated 269 will have an RCM result indicating BCC is present.
- Of these, 128 (48%) will not have a BCC (known as a false positive result), including as many as 19 people with
melanomas mistaken for BCCs.
- Of the 732 people with an RCM result indicating that BCC is not present, 9 (1%) will actually have BCC.
There was not enough evidence to determine the accuracy of RCM for the detection of cSCC in either population group.
How reliable are the results of this review?
There was lots of variation in the results of the studies in this review. Poor reporting of study conduct made assessment of
the reliability of studies difficult. It is unclear whether studies are representative of populations eligible for testing with RCM,
and test interpretation was often undertaken using images, remotely from the patient and the interpreter blinded to clinical
information that would normally be available in practice. Only one study compared the accuracy of dermoscopy and RCM.
Most studies were conducted by specialist research teams with high levels of training and experience with RCM, meaning
that RCM may appear better than it would be when used in everyday practice. Most studies reported diagnosis based on
observers’ subjective views, which might not be the same for people using the technique in everyday practice. In nine
studies, the diagnosis of skin cancer was made by a skin biopsy or by following up those people over time to make sure they
remained negative for skin cancer* .This is likely to have been a reliable method for deciding whether patients really had skin
cancer. In one study, the absence of skin cancer was made by experts looking at the skin, a method that may be less reliable
for deciding whether patients really had skin cancer.
Who do the results of this review apply to?
Five studies were carried out in Europe (61%), and the rest in Asia, Oceania, North America or more than one continent. The
average ages of people who took part ranged from 41 to 65 years. The percentage of people with BCC in these studies
ranged from 6% to 83% (a middle value of 12% for any suspicious lesion and 15% for difficult to diagnose skin lesions). For
studies of RCM used for cSCC, the percentage of people with cSCC ranged between 4% and 13%. In many studies it was
not clear what tests people taking part had received before RCM.
What are the implications of this review?
There is not enough good evidence to support the use of RCM for the diagnosis of BCC or cSCC outside of research studies.
There is a lot of variation and uncertainty in results and in the ways studies were carried out, reducing the reliability of
findings. Using RCM might avoid the need for a diagnostic biopsy in people who see a doctor with a high suspicion of a BCC
lesion, but more research is needed to confirm this. Such research should compare RCM to dermoscopy in well-described
groups of people with suspicious skin lesions and they must say whether other skin cancers end up being missed or being
wrongly classified as BCC.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy or clinical follow up were the reference standards.
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Background 
Target condition being diagnosed
The commonest skin cancers in Caucasian populations are those arising from keratinocyte cells: basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cSCC) (Gordon 2013; Madan 2010). Basal cell carcinoma is by far the
most frequent of the two keratinocyte carcinomas, and around one third of people with a BCC will develop at least a
second BCC over time (Flohil 2013). In 2003, the World Health Organization estimated that between two and three
million ‘non-melanoma’ skin cancers (of which BCC and cSCC are estimated to account for around 80% and 16% of
cases respectively) and 132,000 melanoma skin cancers occur globally each year (WHO 2003).
In this diagnostic test accuracy review we collectively refer to BCC and cSCC using the new preferred and more
accurate term of 'keratinocyte carcinoma' (Karimkhani 2015). We define (a) basal cell carcinoma and (b) squamous
cell carcinoma as the primary target conditions for this review. We will also examine accuracy for the target condition
of (c) any skin cancer, including keratinocyte skin cancer, melanoma or intraepidermal melanocytic variants and any
other skin cancer. We have examined the accuracy of reflectance confocal microscopy for the diagnosis of melanoma
in another review (Dinnes 2018a) which is one of a series of systematic reviews of diagnostic tests for the diagnosis
of keratinocyte skin cancers (Dinnes 2015). A table of acronyms used is provided in Appendix 1.
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including from the bulge and interfollicular epidermis (Grachtchouk 2011
). BCC growth is usually localised, but it can infiltrate and damage surrounding tissue, sometimes causing
considerable destruction and disfigurement, particularly when located on the face (Figure 1). The four main types of
BCC are superficial, nodular, morphoeic, and pigmented. BCCs typically present as slow-growing asymptomatic
papules, plaques, or nodules which may bleed or form ulcers that do not heal (Firnhaber 2012). It is often diagnosed
incidentally rather than by people presenting with symptoms (Gordon 2013). A systematic review of the worldwide
incidence of keratinocyte skin cancers found estimates for BCC generally under 100 per 100,000 across Europe,
ranging from around 900 per 100,000 up to 1800 per 100,000 for some parts of Australia (Lomas 2012).
BCC most commonly occurs on sun-exposed areas of the head and neck (McCormack 1997) and are more common in
men and in people over the age of 40. A rising incidence of BCC in younger people has been attributed to increased
recreational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah 2013). Other risk factors include Fitzpatrick
skin types I and II (Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer history; immunosuppression; arsenic
exposure; and genetic predisposition, such as in basal cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced an average increase of 5.5% per year over the last
four decades, the USA 2% per year, while estimates for the UK show incidence appears to be increasing more steeply
at a rate of an additional 6 / 100,000 persons per year (Lomas 2012). The rising incidence has been explained
by an ageing population, changes in the distribution of known risk factors, particularly ultraviolet radiation, and
improved detection due to the increased awareness amongst both practitioners and the general population (Verkouteren
2017).
According to National Institute for Health and Care Excellence (NICE) guidance (NICE 2010), low risk BCCs that may
be considered for excision are nodular lesions occurring in patients older than 24 years old who are not
immunosuppressed and without Gorlin's syndrome. Furthermore, the lesions should be located below the clavicle;
should be small (< 1 cm) with well-defined margins; not recurrent following incomplete excision; and not in awkward or
highly visible locations (NICE 2010). Superficial BCCs are also typically low risk and may be amenable to medical
treatments such as photodynamic therapy or topical chemotherapy (Kelleners-Smeets 2017). Assigning BCCs as low or
high risk influences the management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can arise from long-standing untreated lesions or from a recurrence of aggressive
basal cell carcinoma after primary treatment (Lear 2012). Very rarely, BCC metastasises to regional and distant
sites resulting in death, especially cases of large neglected lesions in those who are immunosuppressed or those
with Gorlin syndrome (McCusker 2014). Rates of metastasis are reported at 0.0028% to 0.55% (Lo 1991), with very poor
survival rates.
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis or its appendages. People with cSCC often present
with an ulcer or firm (indurated) papule, plaque, or nodule (Griffin 2016) often with an adherent crust and poorly
defined margins (Madan 2010). cSCC can arise in the absence of a precursor lesion or it can develop from pre-existing
lesions, such as actinic keratosis or Bowen's disease (considered by some to be cSCC in situ) with an estimated annual
risk of progression of <1% to 20% (Alam 2001) and 5% respectively (Kao 1986). It remains locally invasive for a
variable length of time, but has the potential to spread to the regional lymph nodes or via the bloodstream to distant
sites, especially in immunosuppressed individuals (Lansbury 2010). High risk lesions are those arising on the lip or
ear, recurrent cSCC, lesions arising on non-exposed sites, scars or chronic ulcers, tumours more than 20mm in
diameter and depth of invasion more than 4mm and poor differentiation on pathological examination (Motley 2009). A
systematic review of incidence studies found that the highest reported incidence of cSCC in Europe was in
Switzerland, at 28.9/100,000 person-years (1997 data), with rates generally lower in Northern European countries (Lomas
2012). Incidence is higher in the USA and Australia, with rates in men of 60/100,000 person-years reported in Alberta,
290/100,000 in Arizona, and 387/100,000 person-years in Australia (Lomas 2012). Based on data from 2000 to 2006,
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the annual incidence rates of cSCC in England, Scotland, and Northern Ireland were 22.7 per 100,000, 27.0 per
100,000, and 30.6 per 100,000 person-years, respectively (Lomas 2012).
Chronic ultraviolet light exposure through recreation or occupation is strongly linked to cSCC occurrence (Alam 2001). It
is particularly common in people with fair skin and in less common genetic disorders of pigmentation, such as albinism,
xeroderma pigmentosum, and recessive dystrophic epidermolysis bullosa (RDEB) (Alam 2001). Other recognised
risk factors include immunosuppression; chronic wounds; arsenic or radiation exposure; certain drug treatments,
such as voriconazole and BRAF mutation inhibitors; and previous skin cancer history (Baldursson 1993; Chowdri 1996; 
Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996; O'Gorman 2014). In solid organ transplant recipients,
cSCC is the most common form of skin cancer; the risk of developing cSCC has been estimated at 65 to 253 times
that of the general population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local and metastatic
recurrence of cSCC at five years is estimated at 8% and 5% respectively. The five-year survival rate of
metastatic cSCC of the head and neck is around 60% (Moeckelmann 2018).
Treatment
Treatment options for BCC and cSCC include surgery, other destructive techniques and topical chemotherapy. A
Cochrane Review of 27 randomised controlled trials (RCTs) of interventions for BCC found very little good quality
evidence for any of the interventions used (Bath-Hextall 2007b). Complete surgical excision of primary BCC has a
reported five-year recurrence rate of <2% (Griffiths 2005; Walker 2006), leading to significantly fewer recurrences than
treatment with radiotherapy (Bath-Hextall 2007b). Mohs micrographic surgery, whereby horizontal sections of the
tumour are microscopically examined and re-excision is undertaken until the margins are tumour-free, can be
considered for high risk lesions on the face where standard wider excision margins might lead to considerable
functional or cosmetic impairment (Bath-Hextall 2007b; Motley 2009; Lansbury 2010; Stratigos 2015). Bath-Hextall and
colleagues (Bath-Hextall 2007b) found a single trial comparing Mohs micrographic surgery with a 3mm surgical
margin excision in BCC (Smeets 2004); the update of this study showed non-significantly lower recurrence at 10 years
with Mohs micrographic surgery (4.4% compared to 12.2% after surgical excision, P = 0.10) (van Loo 2014).
The main treatments for high risk BCC are excision or Mohs micrographic surgery and radiotherapy. For low risk or
superficial subtypes of BCC, or for those with small or multiple BCCs, or both, at low risk sites (Marsden 2010),
destructive techniques other than excisional surgery may be used (e.g. electrodessication and curettage or cryotherapy
(Alam 2001; Bath-Hextall 2007b)). Alternatively non-surgical (or non-destructive) treatments may be considered,
including topical chemotherapy such as imiquimod and 5-fluorouracil and photodynamic therapy (Bath-Hextall 2007b; Kim
2014; Roozeboom 2016; Williams 2017; Drew 2017). Non-surgical treatments are most frequently used for superficial
forms of BCC, with one head to head trial suggesting topical imiquimod is superior to PDT and 5-FU (Jansen 2017).
Although non-surgical techniques are increasingly used, they do not allow histological confirmation of tumour clearance,
and their use is dependent on accurate characterisation of the histological subtype and depth of tumour. The 2007
systematic review of BCC interventions found limited evidence from very small RCTs for these approaches (Bath-Hextall
2007b), which have only partially been filled by subsequent studies (Bath-Hextall 2014; Kim 2014; Roozeboom 2012).
Most BCC trials have compared interventions within the same treatment class, and few have compared medical versus
surgical treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway inhibitor is now available for the treatment of metastatic or
locally advanced BCC based on the pivotal study ERIVANCE BCC (Sekulic 2012). It is licensed for use in these
patients where surgery or radiotherapy is inappropriate, e.g. for treating locally advanced periocular and orbital BCCs
with orbital salvage of patients who otherwise would have required exenteration (Wong 2017). However, NICE has
recently recommended against the use of vismodegib based on cost-effectiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only one RCT eligible for inclusion (Lansbury 2010). Current
practice therefore relies on evidence from observational studies, as reviewed in Lansbury 2013, for example. Surgical
excision with predetermined margins is usually the first-line treatment (Motley 2009; Stratigos 2015). Estimates of
recurrence after Mohs micrographic surgery, surgical excision, or radiotherapy, which are likely to have been
evaluated in higher risk populations, have shown pooled recurrence rates of 3%, 5.4% and 6.4%, respectively with
overlapping confidence intervals; the review authors advise caution when comparing results across treatments (Lansbury
2013).
Index test(s)
Reflectance confocal microscopy (RCM), also known as confocal laser scanning microscopy or confocal
microscopy, was first developed for skin imaging in the early 1990s (Rajadhyaksha 1995) and is emerging as a potential
alternative or adjunct to dermoscopy for the diagnosis of skin cancer. It is a non-invasive technology, which can be used to
visualise horizontally sectioned images of the skin at a cellular lateral resolution of ~1micron, in vivo to the depth of the upper
dermis. The contrast for the monochrome images produced is achieved by the variation of the optical properties within the
skin when illuminated by a near-infrared light (830nm) (see Figure 2). The greatest contrast is achieved from melanin, so that
RCM is advocated as being particularly useful for assessing pigmented lesions.
The Caliber ID VivaScope® imaging systems are the only commercially available RCM devices (distributed by MAVIG in
Europe; www.vivascope.de/en/home.html). The Vivascope 1500 (and the previously available 1000 version) is a
console based unit with a dermoscopic attachment, whereas the Vivascope 3000 is a handheld device designed for
superior ergonomics, allowing imaging of lesions inaccessible for the 1500 version (Figure 3). Imaging can be
undertaken by clinicians or technicians following appropriate training (Edwards 2016). The length of time required for
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diagnosis has been estimated at 15 minutes for Vivascope 1500 (10 minutes of a technician’s time for imaging and
5 minutes of a dermatologists for image interpretation) and 10 minutes for Vivascope 3000 (Edwards 2016). The
company has estimated the average cost per use of the 1500 system, including dermoscopy, as £120 based on
2014 NHS reference costs and an indicative price for Vivascope 1500 of £95,224 (Edwards 2016).
Various algorithms have been proposed for the interpretation of RCM images, particularly for the diagnosis of
melanoma (Dinnes 2018a); however, evaluation of lesion characteristics associated with other types of skin cancer,
especially BCC, is ongoing (Gonzalez 2002; Guitera 2012). The lesion characteristics most recently proposed to be
associated with BCC include the presence of 'dark silhouettes' or 'bright tumour islands' plus at least one of:
‘streaming’ polarization of nuclei in neoplastic aggregates along the same axis of orientation; ‘peripheral palisading’
of nuclei at the tumour islands’ periphery; dark ‘peritumoral clefts’ around the tumour islands; fibrotic stroma with
‘thickened collagen bundles’; dilated and tortuous ‘linear blood vessels’ and ‘coiled blood vessels’; ‘bright dendritic
structures’ within tumour islands; and ‘bright round cells’ in the stroma. Nevertheless, BCC and cSCC specific
criteria have yet to be fully established, with some suggestion that the keratotic surface of SCC may prohibit the use
of imaging techniques (Edwards 2016).
Clinical Pathway 
The diagnosis of skin lesions occurs in primary, secondary, and tertiary care settings by both generalist and specialist
healthcare providers. In the UK, people with concerns about a new or changing lesion will present to their general
practitioner rather than directly to a specialist in secondary care. If the general practitioner has concerns then he/she
usually refers the patient to a specialist in secondary care – usually a dermatologist but sometimes to a surgical
specialist such as a plastic surgeon or an ophthalmic surgeon. Suspicious skin lesions may also be identified in a
referral setting, for example by a general surgeon, and referred for a consultation with a skin cancer specialist (Figure 4).
Skin cancers identified by other specialist surgeons (such as an ear, nose, and throat (ENT) specialist or maxillofacial
surgeon) will usually be diagnosed and treated without further referral.
Current UK guidelines recommend that all suspicious pigmented lesions presenting in primary care should be
assessed by taking a clinical history and visual inspection using the seven-point checklist (MacKie 1990); lesions
suspected to be melanoma or cSCC (London Cancer Alliance 2013) should be referred for appropriate specialist
assessment within two weeks (Chao 2013; Marsden 2010; NICE 2015). Evidence is emerging, however, to suggest
that excision of melanoma by general practitioners (GPs) is not associated with increased risk compared with
outcomes in secondary care (Murchie 2017). In the UK, low risk BCC are usually recommended for routine referral, with
urgent referral for those in whom a delay could have a significant impact on outcomes, for example due to large lesion
size or critical site (NICE 2015). Appropriately qualified generalist care providers increasingly undertake management of
low-risk BCC in the UK (NICE 2010) and Australia (CCAAC Network 2008).
For referred lesions, the specialist clinician will use history-taking, visual inspection of the lesion (in conjunction
with other skin lesions), and palpation of the lesion and associated lymph nodes in conjunction with dermoscopic
examination to inform a clinical decision. If melanoma is suspected, then urgent 2mm excision biopsy is
recommended (Lederman 1985; Lees 1991); for cSCC, predetermined surgical margin excision or a diagnostic biopsy may
be considered. BCC and pre-malignant lesions potentially eligible for nonsurgical treatment may undergo a diagnostic biopsy
before initiation of therapy if there is diagnostic uncertainty. Equivocal (or more difficult to diagnose) melanocytic lesions for
which a definitive clinical diagnosis cannot be reached may undergo surveillance to identify any lesion changes that would
indicate excision biopsy or reassurance and discharge for those that remain stable over a period of time.
Theoretically, teledermatology consultations may aid appropriate triage of lesions into urgent referral; non-urgent secondary
care referral (e.g. for suspected basal cell carcinoma); or where available, referral to an intermediate care setting, e.g. clinics
run by GPs with a special interest in dermatology. The distinction between setting and examiner qualifications and
experience is important as specialist clinicians might work in primary care settings (for example, in the UK, GPs with a
special interest in dermatology and skin surgery who have undergone appropriate training), and generalists might practice in
secondary care settings (for example, plastic surgeons who do not specialise in skin cancer). The level of skill and
experience in skin cancer diagnosis will vary for both generalist and specialist care providers and will also impact on test
accuracy.
Prior test(s)
The diagnosis of skin cancer is based on history-taking and clinical examination. In the UK, this is typically
undertaken at two decision points – first in the GP surgery where a decision is made to refer or not to refer, and then
a second time by a dermatologist or other secondary care clinician where a decision is made to biopsy or excise or
not. Visual inspection of the skin is undertaken iteratively, using both implicit pattern recognition (non-analytical
reasoning) and more explicit ‘rules’ based on conscious analytical reasoning (Norman 2009), the balance of which
will vary according to experience and familiarity with the diagnostic question. Various attempts have been made to
formalise the “mental rules” involved in analytical pattern recognition for melanoma (Friedman 1985; Grob 1998; MacKie
1985; MacKie 1990; Sober 1979; Thomas 1998); however, visual inspection for keratinocyte skin cancers relies
primarily on pattern recognition. Accuracy has been shown to vary according to the expertise of the clinician. Primary
care physicians have been found to miss over half of BCC (Offidani 2002) and to inappropriately diagnose one third
of BCC (Gerbert 2000). In contrast, an Australian study found that trained dermatologists were able to detect 98% of
BCC, but with a specificity of only 45% (Green 1988).
A range of technologies have emerged to aid diagnosis to reduce the number of diagnostic biopsies or
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inappropriate surgical procedures. Dermoscopy using a hand-held microscope has become the most widely used
tool for clinicians to improve diagnostic accuracy of pigmented lesions, in particular for melanoma (Argenziano 1998; 
Argenziano 2012; Haenssle 2010; Kittler 2002), although is less well established for the diagnosis of BCC or cSCC.
The diagnostic accuracy, and comparative accuracy, of visual inspection and dermoscopy for keratinocyte skin cancer
has been evaluated in a further review in this series (Dinnes 2018b).
Role of index test(s)
RCM is most likely to have a role as an additional test to better identify lesions that can be monitored or reassured
as being benign, instead of being sent for urgent excision (Edwards 2016), or for low risk BCC to identify those eligible for
non-surgical treatment without the need for a diagnostic biopsy. RCM could also be considered as a primary diagnostic test,
i.e. as a potential replacement for dermoscopy.
Delay in diagnosis of a BCC as a result of a false-negative test is not as serious as for melanoma because BCCs are
usually slow-growing and very unlikely to metastasise (Betti 2017). However, delayed diagnosis can result in a larger and
more complex excision with consequent greater morbidity. Very sensitive diagnostic tests for BCC however may compromise
on lower specificity leading to a higher false-positive rate, and an enormous burden of skin surgery, such that a balance
between sensitivity and specificity is needed. The situation for cSCC is more similar to melanoma in that the consequences
of falsely reassuring a person that they do not have skin cancer can be serious and potentially fatal. Thus, a good diagnostic
test for cSCC should demonstrate high sensitivity and a corresponding high negative predictive value. A test that can reduce
false positive clinical diagnoses without missing true cases of disease has patient and resource benefits. False-positive
clinical diagnoses not only cause unnecessary morbidity from the biopsy, but could lead to initiation of inappropriate
therapies and also increase patient anxiety.
A further postulated advantage of RCM is its ability to non-invasively differentiate seborrhoeic keratoses or non-
melanocytic lesions from a population of pigmented lesions (de Carvalho 2015; Nascimento 2014; Menge 2016).
RCM could also develop a role in guiding definitive therapeutic margins (Edwards 2016), both pre- and intra-operatively and
to estimate response to topical chemotherapy for lentigo maligna and potentially BCCs; however, these uses are not under
consideration in this review.
Alternative test(s)
A number of other tests have been reviewed as part of our series of Cochrane DTA reviews on the diagnosis of
keratinocyte skin cancers, including visual inspection and dermoscopy (Dinnes 2018b), teledermatology (Chuchu 2018a
), mobile phone applications (Chuchu 2018b), computer-assisted diagnosis (CAD) techniques (Ferrante di Ruffano 2018a
), optical coherence tomography (OCT) (Ferrante di Ruffano 2018b), exfoliative cytology (Ferrante di Ruffano 2018c)
and high frequency ultrasound (Dinnes 2018c).
OCT is an emerging optical imaging technology based on interferometry using a near infra-red light source. It exploits
differences in the refractive index in the skin to create vertically sectioned images in vivo, in real time and has a
relatively high depth of penetration, allowing dermal lesions to be delineated (Olsen 2015). OCT is considered to be
particularly useful for the differentiation of non pigmented lesions. Pigmented lesions produce regular scattering
patterns which inhibit the differentiation of malignant from benign lesions (Olsen 2015; Gambichler 2015). The
use of high frequency ultrasound has been advocated in diagnosing a range of skin conditions, including skin
cancer, infection, and inflammatory conditions (Kleinerman 2012), with malignant lesions reportedly appearing as
hypoechogenic areas surrounded by a hyperechogenic dermis. Melanomas in particular also reportedly appear homogenous
and with well-defined margins (e.g. Harland 2000). CAD or artificial intelligence-based techniques process and
manipulate lesion data using predefined algorithms to identify the features that discriminate malignant from benign
lesions (Rajpara 2009; Esteva 2017). These techniques have been incorporated into commercially available
handheld devices for ease of use in a clinic setting, including SIAscopy™ (Moncrieff 2002; Walter 2012), MelaFind®
(Monheit 2011; Wells 2012; Hauschild 2014), and the Nevisense™ Electrical Impedance Spectroscopy system (Malvehy
2014). CAD has however most commonly been applied to digital dermoscopy images (Rajpara 2009; Esteva 2017).
Evidence permitting, the accuracy of available tests will be compared in an overview review, exploiting within-study
comparisons of tests and allowing the analysis and comparison of commonly used diagnostic strategies where tests may be
used singly or in combination.
We are not considering the accuracy of histopathological confirmation following lesion excision or biopsy as an index test for
these reviews; it is the established reference standard for skin cancer diagnosis and will be one of the standards against
which we will evaluate the index tests in these reviews.
Rationale
Our series of reviews of diagnostic tests used to assist the clinical diagnosis of the keratinocyte skin cancers BCC and cSCC,
aims to identify the most accurate approaches to diagnosis and provide clinical and policy decision-makers with the highest
possible standard of evidence on which to base decisions. With the increasing availability of a wider range of tests, there is a
need to differentiate and appropriately triage keratinocyte skin cancers to avoid sending too many people with benign or low
risk lesions for a specialist opinion and possible excision or biopsy, whilst not missing those people who have lesions that
require treatment.
Although a set of billing codes for the USA have been agreed since January 2016 (Rajadhyaksha 2017), RCM is not
recommended for routine use in the UK (Edwards 2016), Australia (Guitera 2017), or New Zealand (Sobarun 2015).
To date, the use of RCM has been limited by expense (in terms of both equipment and staff time) and the need for
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specialised training. Recent studies have demonstrated high sensitivity and specificity amongst experienced RCM
users, however, in at least one study, the accuracy of the group on average was higher than that of any one
individual observer (Farnetani 2015). Our own systematic review of 18 studies of RCM for the diagnosis of melanoma
suggested that although RCM may augment diagnostic sensitivity when used in conjunction with clinical inspection
and dermoscopy, its main contribution is an increase in specificity, reducing the number of individuals receiving
unnecessary surgery by up to three quarters compared to dermoscopy (Dinnes 2018a).
Available systematic reviews of RCM for keratinocyte skin cancers are limited by out of date searches and methods. Xiong
2016 failed to consider differences in study populations and varying definitions of the target condition, and used an out of
date meta-analytic approach. Mogensen 2007 did not report the use of systematic methods for study inclusion or extraction
and did report undertaking quality assessment, while Edwards 2016 focused on selected studies considered to be more
applicable to a UK setting. In this rapidly advancing field, there is a need for an up-to-date analysis of the accuracy of RCM
for the diagnosis of keratinocyte skin cancer.
This is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of melanoma and
keratinocyte skin cancers as part of the National Institute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 2 shows the content and structure of the programme. As several reviews for each topic area
followed the same methodology, generic protocols were prepared in order to avoid duplication of effort, one for
diagnosis of keratinocyte skin cancers (Dinnes 2015) and one for diagnosis of melanoma (Dinnes 2015a). The
Background and Methods sections of this review therefore use some text that was originally published in the protocol
concerning the evaluation of tests for the diagnosis of keratinocyte skin cancer (Dinnes 2015) and text that overlaps
some of our other reviews (Dinnes 2018a).
Objectives 
To determine the diagnostic accuracy of reflectance confocal microscopy (RCM) for the detection of BCC in adults, and to
compare its accuracy with visual inspection or dermoscopy or both.
To determine the diagnostic accuracy of RCM for the detection of cSCC in adults, and to compare its accuracy with visual
inspection or dermoscopy, or both.
Accuracy was estimated separately according to the point in the clinical pathway at which RCM was evaluated:
in participants with any suspicious lesion, where RCM might be used as an alternative to dermoscopy or to supplement1.
visual inspection alone
in participants with equivocal (or more difficult to diagnose) lesions in whom a clear management decision could not be2.
made following visual inspection and dermoscopy, where RCM might be used as an addition to visual inspection or
dermoscopy, or both.
Studies that did not clearly fit into either of these two groups were considered as 'other lesion' studies. The terms equivocal
and 'difficult to diagnose' have been used, and should be interpreted, interchangeably throughout this review.
Secondary objectives
To determine the diagnostic accuracy of RCM for the detection of any skin cancer in adults, where keratinocyte skin cancers
make up at least 50% of included skin cancers, and to compare its accuracy with visual inspection or dermoscopy, or both.
Accuracy was estimated separately according to the point in the clinical pathway at which RCM is evaluated:
where it might be used as an alternative to dermoscopy in participants with any lesion suspicious for melanoma1.
where it might be used as an addition to visual inspection or dermoscopy, or both, in participants with equivocal lesions in2.
whom a clear management decision could not be made following visual inspection and dermoscopy alone
For the detection of BCC or cSCC (the primary target conditions):
i. To compare the accuracy of RCM to dermoscopy where both tests have been evaluated in the same studies (direct test
comparisons)
ii. To determine the diagnostic accuracy of individual algorithms for RCM
iii. To determine the effect of observer experience.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity for investigation across our series of reviews, as
outlined in our generic protocol (Dinnes 2015) and described in Appendix 3; however, our ability to investigate these was
necessarily limited by the available data on each individual test reviewed.
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
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studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series' of participants unselected by true disease status (referred to as case series for the purposes of
this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005).
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data, or if they included less than five cases of BCC or
cSCC or less than five benign lesions.
Participants
We included studies in adults with lesions suspicious for skin cancer.
We excluded studies that recruited only participants with malignant diagnoses and studies that compared test results
in participants with malignancy compared with test results based on 'normal' skin as controls, due to the bias inherent
in such comparisons (Rutjes 2006).
We excluded studies conducted in children or which clearly reported more than 50% of participants aged 16 and under.
Index tests
Studies evaluating RCM alone, or RCM in comparison to usual practice (visual inspection or dermoscopy, or both) were
included.
All established algorithms or checklists to assist diagnosis by RCM were included. Studies developing new algorithms or
methods of diagnosis (i.e. derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with BCC or cSCC and the study
reported accuracy based on the presence or absence of particular combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no
separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy.
No exclusions were made according to test observer.
Target conditions
Two primary target conditions were defined as the detection of:
basal cell carcinoma (BCC), including all subtypes;
invasive cutaneous squamous cell carcinoma (cSCC) (we did not consider cutaneous SCC in situ or Bowen's disease as
disease positive)
An additional definition of the target condition was considered in secondary analysis, the detection of:
any skin cancer, including BCC, cSCC, melanoma or any rare skin cancer (e.g. Merkel cell cancer), as long as skin
cancers other than melanoma made up more than 50% of the disease positive group. Data from studies in which
melanoma accounted for more than 50% of skin cancers were included in the review of RCM for the diagnosis of
melanoma (Dinnes 2018a).
Reference standards
The ideal reference standard was histopathological diagnosis in all eligible lesions. A qualified pathologist or
dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing a minimum
dataset to include the type of skin cancer (BCC, cSCC) and subtype of BCC and may also refer to the TNM (tumour, node,
and metastasis) classification of staging for cSCC (Royal College of Pathologists 2014). We did not apply the reporting
standard as a necessary inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy are unlikely to be carried out for all benign-appearing lesions within a representative population
sample. Therefore, we accepted clinical follow-up of benign-appearing lesions as an eligible reference standard, whilst
recognising the risk of differential verification bias (as misclassification rates of histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as it is not carried out within
the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses are
presented (as for cancer registry follow up), it may be difficult to determine whether the detection of a malignant lesion during
follow-up is the same lesion that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
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all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 2 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease-related terms with terms related to the test
names, using both text words and subject headings was formulated. The search strategy was designed to capture
studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the
searches for tests for staging of disease, a filter using terms related to cancer staging and to accuracy indices was
applied to the staging test search, to try to eliminate irrelevant studies, for example, those using imaging tests to
assess treatment effectiveness. A sample of 300 records that would be missed by applying this filter was screened
and the filter adjusted to include potentially relevant studies. When piloted on MEDLINE, inclusion of the filter for
the staging tests reduced the overall numbers by around 6000. The final search strategy, incorporating the filter (Appendix
4), was subsequently applied to all bibliographic databases as listed below. The final search result was cross-checked
against the list of studies included in five systematic reviews; our search identified all but one of the studies, and this study is
not indexed on MEDLINE. The Information Specialist devised the search strategy, with input from the Information Specialist
from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied.
Searching other resources 
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We
have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77) between
screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any test used to
investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix 3) were
applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a methodologist
reviewer (JDi or NC) to all full text articles, disagreements were resolved by consensus or by a third party (JDe, CD, HW, and
RM). Authors of eligible studies were contacted when insufficient data were presented to allow for the construction of 2x2
contingency tables.
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Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information relating to the diagnostic threshold was missing. Authors of
conference abstracts published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper
was identified, we marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 6). The modified QUADAS-2 tool was piloted on a small number of included full text articles. One
clinical and one methodologist reviewer (JDi, NC or LFR) independently assessed quality for the remaining studies; any
disagreement was resolved by consensus or by a third party where necessary (JDe, CD, HW, and RM).
Statistical analysis and data synthesis
For the detection of each definition of the target condition, we conducted separate analyses according to the point in the
clinical pathway that RCM was applied. Three groups of studies were formed:
i. RCM used in participants with any lesion suspicious for skin cancer, i.e. no attempt to exclude those diagnosed as obvious
BCCs or SCCs or as clearly benign on visual inspection or dermoscopy was described (denoted as studies in ‘any suspicious
lesion’)
ii. RCM used as an addition to dermoscopy in participants with equivocal lesions in whom a clear management decision
could not be made following visual inspection and dermoscopy (denoted as studies in ‘equivocal’ lesions)
iii. ‘Other’ studies which did not fit into either of these categories
Our unit of analysis for all analyses was the lesion rather than the patient. This is because (i) in skin cancer initial treatment is
directed to the lesion rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each
person), and (ii) it is the most common way in which the primary studies reported data. Although there is a theoretical
possibility of correlations of test errors when the same people contribute data for multiple lesions, most studies include very
few people with multiple lesions and any potential impact on findings is likely to be very small, particularly in comparison with
other concerns regarding risk of bias and applicability. For each analysis undertaken, only one dataset was included per
study to avoid over-counting of lesions. Where multiple thresholds were assessed in an individual study, datasets for correct
diagnosis of each type of malignancy were selected as opposed to data for the decision to excise lesions. If data for multiple
observers was reported, data for the most experienced observer was used, and data for a single observer’s diagnosis was
used in preference to a consensus or average across observers. If we were unable to choose a dataset based on the above
‘rules’, a random selection of one dataset per study was made.
For each index test, algorithm or checklist under consideration, estimates of sensitivity and specificity were plotted on
coupled forest plots and in receiver operating characteristic (ROC) space. For tests where commonly used thresholds
were reported we estimated summary operating points (summary sensitivities and specificities) with 95% confidence and
prediction regions using the bivariate hierarchical model (Chu 2006; Reitsma 2005). Where inadequate data were
available for the model to converge the model was simplified, first by assuming no correlation between estimates
of sensitivity and specificity and secondly by setting estimates of near zero variance terms to zero (Takwoingi 2017). Where
all studies reported 100% sensitivity (or 100% specificity) the number with disease (or no disease) was summed across
studies and used to compute a binomial exact 95% confidence interval. Heterogeneity in estimates of sensitivity and
specificity was assessed by inspection of the magnitude and statistical significance of the estimates of variance terms in the
bivariate model.
Data on the accuracy of visual inspection or dermoscopy, to allow comparisons of tests, was included only if reported
in the studies of RCM due to the known substantial unexplained heterogeneity in all studies of the accuracy of these
tests (Dinnes 2018a). Comparisons were made between tests using RCM data from all RCM studies, and then
only using RCM data from studies that also reported visual inspection or dermoscopy data for the same patients to
enable a robust direct comparison (Takwoingi 2013).
For computation of likely numbers of true positive, false positive, false negative and true negative findings in the Summary of
Findings tables, summary sensitivity and specificity estimates were applied to lower quartile, median and upper quartiles of
the prevalence observed in the study groups.
Bivariate models were fitted using the meqrlogit command in STATA 13.
Investigations of heterogeneity
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We initially examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity and
summary ROC plots. Where a sufficient number of studies were identified, meta-regression was performed by adding the
potential source of heterogeneity as a covariate to a hierarchical model.
Sensitivity analyses
No sensitivity analyses were performed.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), no tests to detect publication bias were performed.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer. Of
the 1051 full text papers assessed, 848 were excluded from all reviews in our series (see Figure 5 PRISMA flow diagram of
search and eligibility results).
Of the 83 studies tagged as potentially eligible for the two RCM reviews, 22 publications were included, reporting 22
individual studies: 10 in this review and 18 in the review of RCM for the detection of melanoma (6 were included in both).
Reasons for exclusion included publications not being primary test accuracy studies (n=14), lack of test accuracy data (6
studies), because they were derivation studies developing new algorithms or approaches to diagnosis without the use of
separate training and test sets of data (n=5), included ineligible populations, e.g. including only malignant lesions (n=6), did
not assess eligible target conditions or did not adequately define the target condition (n=20), inadequate sample size (n=15),
assessed the accuracy of individual RCM characteristics (n=4) or used ineligible reference standards (i.e. less than 50% of
benign group with final diagnosis established by histology or follow-up; n=4). A list of the 73 studies excluded from this
review with reasons for exclusion is provided in Characteristics of excluded studies, with a list of all studies excluded from
the full series of reviews available as a separate pdf.
The corresponding authors of 6 publications were contacted and asked to supply further information for the purposes of
this review. To date, responses have been received from only one author to allow study inclusion (Incel 2015). In addition,
Professor Pellacani provided information on lesion overlap between several identified studies that were co-authored by him.
This review reports on a total of 11 cohorts of participants with lesions suspected of skin cancer, published in 10 study
publications, providing 91 datasets for RCM and 4 for usual practice (visual inspection (n=1) or dermoscopy (n=3)). A total of
2037 lesions with 464 BCCs were included in the 11 datasets reporting data for BCC, and 834 lesions with 71 cSCCs were
included in the 4 datasets reporting data for cSCC. The total number of study participants cannot be estimated due to lack of
reporting in study publications. The Pellacani 2014 study was split into two cohorts for the purposes of this review:
one cohort of lesions equivocal on dermoscopy denoted as the RCM 'consultation' group by the study authors (Pellacani
2014a (cons)); and the other cohort of lesions recommended for excision on the basis of clear cut clinical or
dermoscopic findings, denoted as the RCM 'documentation' group by the study authors (Pellacani 2014b (doc)). A
description of the various algorithms and thresholds used for diagnosis across the studies is provided in Appendix 7.
Methodological quality of included studies
The overall methodological quality of all included study cohorts (n=11) is summarised in Figure 6 and Figure 7. Studies were
generally at high or unclear risk of bias across all domains apart from the index test and of high or unclear concern regarding
applicability of the evidence.
Almost two thirds of cohorts were at high (n=4) or unclear (n=3) risk of bias for participant selection due to exclusion of poor
quality images (n=3), use of a case-control type design (n=1) or unclear participant selection (n=3). All cohorts were at high
(n=8) or unclear (n=3) concern regarding applicability of included participants and setting, due to restricted study populations
(with 4 studies including only participants with lesions suspected of melanoma, two including only those with high clinical
suspicion of BCC, and two with more narrowly defined populations such as nodular lesions or proliferative lesions) and
inclusion of multiple lesions per patient (n=5). Eight of the 11 cohorts included lesions selected for excision based on the
clinical or dermoscopic diagnosis or selected retrospectively from histopathology databases; this was not considered of high
concern regarding applicability for RCM studies as the primary role for RCM is to reduce unnecessary excisions.
All cohorts were at low risk of bias in the index test domain. Over half of studies were high concern for the applicability of the
index test (n=7), due to remote RCM interpretation (n=5), blinding to clinical information (n=3), presentation of consensus
diagnoses only (n=1), lack of detail regarding the diagnostic threshold used (n=2), or interpretation by a non-expert observer
(n=2). It is of note that 8 of the 11 cohorts were produced by, or in collaboration with, the same expert research team, led by
Prof Pellacani which may further reduce the generalisability of results.
One cohort was at low risk of bias for the reference standard, two at high risk due to inadequate reference standards (>20%
of the disease negative group with final diagnosis by follow-up or expert opinion), and 8 at unclear risk due to unclear
blinding of the reference standard to the RCM result. None of the cohorts reported blinding of histology to the referral
diagnosis (based on clinical examination or dermoscopy), but this was not incorporated into the overall risk of bias for this
domain. For the applicability of the reference standard, one was at high risk due to the use of expert observer diagnosis as
the reference standard and 9 were unclear regarding histopathology interpretation by an experienced histopathologist or by a
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dermatopathologist.
For participant flow and timing, three cohorts were at low risk of bias, 5 at high risk and three at unclear risk. Three cohorts
did not use the same reference standard for all participants (differential verification), 7 were unclear on the interval between
the application of the index test and excision for histology, and four did not include all participants in the analysis primarily
due to technical difficulties in imaging.
Findings
1 Target condition: basal cell carcinoma
In this section we present the results for studies of RCM versus visual inspection or dermoscopy for the target condition of
BCC, according to the study population: studies in participants with any lesions suspicious for melanoma versus those in
participants with equivocal lesions. A number of different approaches to RCM diagnosis were used across the included
studies; these are described in detail in Appendix 7. Summary characteristics of studies are provided in Appendix 8. Results
for the primary analyses are presented in Table 1. Forest plots of study data for each analysis in this table are given for each
analysis in Figure 8 with studies plotted in ROC space in Figure 9 and Figure 10. Table 2 and Figure 11 compare results
between observers.
Any suspicious lesion
The following section documents studies where RCM appeared to have been evaluated in participants with any lesion
scheduled for excision. These populations are likely to include both clinically or dermoscopically obvious BCCs, along with a
proportion of more difficult to diagnose (equivocal) lesions so that, RCM was being evaluated as an addition to visual
inspection alone or visual inspection with dermoscopy.
Four studies provided data for the detection of BCC with RCM (Curchin 2011; Guitera 2012; Pellacani 2014b (doc); Rao
2013). A total of 912 lesions were included with 107 cases of BCC. One study provided data for expert and non-expert
observers; however, only 284 of the 334 included lesions were evaluated by both readers (Rao 2013). The total number
of participants cannot be reported due to lack of reporting in two of the four studies (Rao 2013 and Guitera 2012; the latter
reporting overall number of patients but not the number with lesions included in the test set of data).
All studies were case series and undertaken in secondary or specialist clinic settings. Lesions were scheduled for
excision reportedly for cosmetic or medical reasons (Rao 2013), reasons not reported (Curchin 2011), to rule out an
‘epithelial tumour’ or melanoma (Guitera 2012), or due to clinical or dermoscopy suspicion of melanoma (Pellacani 2014b
(doc)). Three studies included any type of lesion, and one restricted to pigmented lesions only (Pellacani 2014b (doc)
). Sample sizes ranged from 50 to 356 lesions. The median lesion to patient ratio in three studies was 1.19 (range
1.07 to 1.20). The mean prevalence of BCC was 13% (range 8% to 18%); the mean prevalence of any malignancy
(BCC, cSCC, or melanoma) was 34% (range 22% to 56%). All studies also reported data for the diagnosis of
melanoma (Dinnes 2018a). Studies generally included a varied spectrum of benign lesions including benign
melanocytic naevi (Guitera 2012; Pellacani 2014b (doc); Rao 2013), Spitz naevi (Guitera 2012; Pellacani 2014b (doc); Rao
2013), and seborrhoeic or actinic keratoses (Guitera 2012; Pellacani 2014b (doc); Rao 2013), or both. In all studies the
reference standard diagnosis was made by histology alone (i.e. all lesions either excised or biopsied).
All four studies used the Vivascope 1500 imaging system; three reporting the use of dermoscopic images to help
guide acquisition of RCM images (Curchin 2011; Guitera 2012; Rao 2013). Diagnosis was reported for a single observer
rather than for a consensus of observers or average value. Observer qualifications were not reported apart from in Guitera
2012 (dermatologists). Three studies were considered to have presented data for expert observers (Guitera 2012; Pellacani
2014b (doc); Rao 2013) and one for novice observers (Curchin 2011). Diagnosis was undertaken in-person with real
time interpretation of RCM images (Curchin 2011; Pellacani 2014b (doc)) or remotely based on RCM images
alongside the dermoscopic image of the same lesion (Guitera 2012; Rao 2013). Rao 2013 also presented data for in-person
diagnosis by a less experienced observer but this was not included in the primary analysis for detection of BCC.
One study developed a new algorithm for detection of melanoma and BCC (data for the BCC element are reported
here) (Guitera 2012), and the other three reported data for the correct diagnosis of each type of malignancy (Curchin 2011; 
Pellacani 2014b (doc); Rao 2013). Estimates of sensitivities ranged from 52% to 100% and specificities from 45% to
100% (Figure 8). The high sensitivity of 100% and low specificity of 45% in Pellacani 2014b (doc) appear as outliers,
all other studies having sensitivities at or below 67% and specificities above 95% (Figure 9). Pellacani 2014b (doc) was the
only study to restrict inclusion to pigmented lesions, and all lesions had ‘consistent clinical and or dermoscopic criteria for
melanoma diagnosis’; it also included no cSCCs in the disease negative group.
Summary sensitivity and specificity for the detection of BCC were 76% (95% CI 45% to 92%) and 95% (95% CI 66% to
99%) (Table 1). Two studies incorrectly identified other skin cancers as BCCs (8/114 false positive diagnoses), including two
melanomas and two cSCCs in Guitera 2012 and four cSCCs in Rao 2013. The other study which included cSCCs (Curchin
2011) reported correct diagnosis of all 6 cSCCs or cSCC precursors.
Equivocal lesion studies
We defined equivocal lesion studies as those in which RCM was used in participants with equivocal lesions in whom a clear
management decision could not be made following visual inspection or dermoscopy, i.e. RCM was being evaluated as a
potential addition to dermoscopy.
Three studies provided data for the detection of BCC with RCM (Farnetani 2015; Pellacani 2014a (cons); Witkowski 2016
), one providing data for nine different observers (Farnetani 2015), and one comparing the diagnosis of the same
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lesions with RCM and using dermoscopic images (Witkowski 2016). A total of 668 lesions were included with 148 cases of
BCC; the total number of participants cannot be reported due to lack of reporting in two studies.
All studies were case series, two of which re-interpreted previously acquired RCM images (Farnetani 2015; Witkowski 2016),
and were undertaken in secondary or specialist clinic settings. Two studies included lesions suspected of being melanoma.
Farnetani 2015 included any clinically equivocal lesion excised due to clinical or dermoscopic suspicion of melanoma, and
Pellacani 2014a (cons) included pigmented lesions from patients requesting a mole check or with suspicion of
melanoma for which an outcome decision could not be reached based on clinical or dermoscopic criteria. One
study (Witkowski 2016) included clinically equivocal ‘pink’ cutaneous lesions with no pigmentation or containing less
than 10% pigment and the absence of pigment network. Sample sizes ranged from 100 to 308 lesions. The
prevalence of BCC was 6% (Pellacani 2014a (cons)), 15% (Farnetani 2015) and 44% (Witkowski 2016), and prevalence of
any malignancy (BCC, cSCC, or melanoma) was 8%, 35% and 53%, respectively (only Witkowski 2016 included
any cSCC). Two studies also reported data for the diagnosis of melanoma (Farnetani 2015; Pellacani 2014a (cons); see also
Dinnes 2018a). Studies included a varied spectrum of benign lesions, Farnetani 2015 and Pellacani 2014a (cons) including
predominantly benign melanocytic naevi and Witkowski 2016 included a relatively larger proportion of benign
keratotic lesions and dermatofibromas (Appendix 8). In two studies the reference standard diagnosis was made by
histology alone (Farnetani 2015; Witkowski 2016); Pellacani 2014a (cons) reported histological diagnosis for the 81 lesions
initially recommended for excision, with sequential digital follow-up in the remaining 74% (227/308) of lesions; 28 of these (all
found to be benign) were later excised due to changes identified on follow-up.
All studies used the Vivascope 1500 imaging system and diagnosis was reported for single observers, with
Farnetani also reporting the average across 9 observers and for the majority diagnosis (5 of 9 evaluators in
agreement). Observers were dermatologists (Farnetani 2015), assumed to be dermatologists (Witkowski 2016), or
RCM described as conducted in a ‘confocal unit’ (Pellacani 2014a (cons)). Diagnosis was undertaken in-person
with real time interpretation of RCM (Pellacani 2014a (cons)) or remotely based on RCM images either alongside
the dermoscopic image of the same lesion (Farnetani 2015) or blinded to all other clinical information (Witkowski 2016).
All three studies reported data for observer diagnosis of BCC. Estimates of sensitivities ranged from 85% to 100% and
specificities from 76% to 94% (Figure 8). The high specificity of 94% (95% CI 89% to 97%) in Witkowski 2016
appeared as an outlier (non-overlapping confidence intervals), the other two studies having specificities of 76%
(95% CI 66% to 85%) (Farnetani 2015) and 79% (95% CI 73% to 83%] (Pellacani 2014a (cons)). Of note, Witkowski 2016
had a markedly different patient population to the other two studies, including only non-pigmented lesions with a markedly
different spectrum of lesion types (see above).
Summary sensitivity and specificity for the detection of BCC were 94% (95% CI 79% to 98%) and 85% (95% CI 72% to
92%) (Table 1). Two studies incorrectly identified other skin cancers as BCCs (15/91 false positive diagnoses) including 14
melanomas in Farnetani 2015 and 1 cSCC in Witkowski 2016.
Witkowski 2016 also presented data for the diagnosis of nonpigmented lesions based on the dermoscopic image alone
(different observers interpreting the RCM and dermoscopic images). Sensitivity and specificity estimates were almost
identical, with test sensitivity 85% (95% CI 77% to 91%) for both tests and specificity 94% (95% CI 89% to 97%) for
RCM compared to 92% (95% CI 87% to 96%) for dermoscopy (Table 1 and Figure 10).
Analyses by algorithms used to assist RCM
The 11 included cohorts of lesions provided 12 datasets evaluating the accuracy of different approaches to diagnosis with
RCM for the detection of BCC. A description of these approaches is provided in Appendix 7.
Only one eligible study was identified that used a formally developed algorithm for the detection of BCC in an any suspicious
lesion population. Guitera 2012 randomly allocated lesions to a training set for algorithm development and a test set
for validation to develop a new two-step algorithm for the detection of melanoma and BCC. Lesions were reported to
be predominantly melanocytic or suspicious for BCC. Applying the features found to be independently significant for
BCC, sensitivity was 65% (95% CI 51% to 78%) and specificity 95% (95% CI 92% to 97%). These results are largely
similar to those of the other studies in ‘any suspicious lesion’ (Figure 8) all of which reported observers’ correct diagnosis of
BCC. All data for ‘equivocal lesion’ populations is also based on observers’ correct diagnosis of BCC without the use of any
formal algorithm.
Two studies reported accuracy for features found to be independently significant for BCC but did not use a separate
training set to ascertain the relevant features (Castro 2015; Longo 2013). Two studies selected lesion
characteristics thought to assist the correct diagnosis of BCC based on previously published literature (Appendix 7) (Incel
2015; Nori 2004). All four studies were classified as ‘other lesion population’ studies, and are covered in more detail below.
All studies reported sensitivities and specificities at or above 90%, apart from specificities of 78% (95% CI 40% to 97%)
reported in Castro 2015, which included only 9 ‘benign’ lesions, and of 78% (95% CI 67% to 87%) in Nori 2004, which
reported only that control group lesions had a 'range of common diagnoses' to BCC (Figure 8).
Analyses by observer experience
The 11 included studies provided 19 datasets evaluating the accuracy of observers with different levels of
expertise; 9 datasets coming from the same study (Farnetani 2015).
Figure 11 provides forest plots of all studies by observer experience, separately for in-person and image-based studies.
Meta-analytical estimates for each group are presented in Table 2. Data for two of the 9 observers (one for high experience
and one for low experience) were randomly sampled from Farnetani 2015. One further study (Rao 2013) provides a
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comparison of a less experienced (in-person diagnosis) observer compared to a more experienced (but image-based
diagnosis) observer; however, the two observers did not examine the same lesions (overlap of 284/334 lesions). We did not
formally make any comparisons between subgroups due to the small number of studies available.
Seven cohorts presented data for observers judged to be expert or experienced in RCM: three were based on in-
person evaluations (Pellacani 2014a (cons); Pellacani 2014b (doc)), or assumed to be in-person (Castro 2015);
four were from image-based evaluations, two where observers were provided with the dermoscopic image of the
same lesion (Farnetani 2015; Rao 2013) and two where observers were blinded to all clinical information (Guitera 2012; 
Longo 2013). The pooled sensitivity for the seven datasets was 98% (95% CI 74% to 100%) and pooled specificity was
87% (95% CI 71% to 95%) (Table 2). Sensitivities were at or above 90% in all studies apart from Guitera 2012 (65%, 95% CI
51% to 78%) and Rao 2013 (52%, 95% CI 32% to 71%). Specificities were more variable (45% to 98%), likely due to
variations in the spectrum of disease (Figure 11).
Four cohorts presented for observers judged to be less experienced or novice: two were based on in-person
evaluations (Curchin 2011; Rao 2013) and two were image-based, one providing observers with the dermoscopic
image of the same lesion (Farnetani 2015) and one blinding observers to all clinical information (Nori 2004). The
pooled sensitivity for the four datasets was 85% (95% CI 69% to 93%) and specificity 91% (95% CI 81% to 96%) (Table 2).
Two studies did not report the experience of RCM observers (Incel 2015; Witkowski 2016) (Table 2).
Investigations of heterogeneity
We were unable to undertake investigations of heterogeneity for other characteristics listed in the protocol due to lack of
data.
2 Target condition: cutaneous squamous cell carcinoma
Two studies reported data for RCM for the target condition of cSCC: one conducted in participants with any lesion
suspicious for melanoma (Rao 2013) and one in comparison to dermoscopy participants with equivocal lesions (Witkowski
2016). Summary characteristics of studies are provided in Appendix 8. Study results are presented in Table 3 with forest
plots of study data in Figure 12. Two further studies present data for cSCC in ‘other’ lesion populations (see ‘Other lesion
populations’ section below).
Rao 2013 included lesions scheduled for excision for cosmetic or medical reasons and presented results for the correct
diagnosis of cSCC for two observers with varying levels of experience based on in-person diagnosis and interpretation of
RCM images alongside dermoscopic images. For the experienced observer assessing RCM images (42 of 323 assessed
were cSCC), sensitivity for the detection of cSCC was 74% (95% CI 58% to 86%) and specificity was 92% (95% CI 88% to
95%). For the less experienced observer, in-person RCM interpretation (39/318 assessed had cSCC) had a lower sensitivity
of 41% (95% CI 26% to 58%) and higher specificity of 97% (95% CI 95% to 99%).
Witkowski 2016 included 260 clinically equivocal ‘pink’ cutaneous lesions and presented results for the correct diagnosis of
cSCC (n = 13) for one observer based on RCM image interpretation and for another observer based on the dermoscopic
image alone; no other clinical information was provided. Sensitivity was the same for both tests 77% (95% CI 46% to 95%),
and specificities were almost identical at 98% for RCM (95% CI 96% to 100%) and 99% for dermoscopy (95% CI 96% to
100%).
3 Target condition: any skin cancer
Four studies reported data for RCM for the target condition of any skin cancer: two were conducted in participants
with any lesion suspicious for melanoma (Curchin 2011; Rao 2013) and two in participants with equivocal lesions (Farnetani
2015; Witkowski 2016). Summary characteristics of studies are provided in Appendix 8. Study results are presented in Table
4 with forest plots of study data in Figure 13.
Both studies in the any suspicious lesion group included lesions scheduled for excision, with diagnosis undertaken in-
person by a novice RCM reader (Curchin 2011) or remotely by an RCM expert based on RCM images (Rao 2013). Both
studies reported data for the observer’s correct diagnosis of each malignancy, and Rao 2013 reported data for the correct
diagnosis of each type of malignancy and for the decision to excise a lesion. Rao 2013 also reported data for in-person
evaluation with RCM by a less experienced observer (data not included due to a prior stated preference for more
experienced observer data). A total of 373 lesions were included with 100 skin cancers (22 melanoma, 36 BCC, and 42
cSCCs), pooled sensitivity was 85% (95% CI 0.77% to 0.91%) and specificity 86% (95% CI 82% to 98%).
One of the two studies in equivocal lesions was conducted in participants with lesions excised due to suspicion for
melanoma (Farnetani 2015) and one in non-pigmented or ‘pink’ lesions (Witkowski 2016). A total of 360 lesions were
included with 175 malignant cases (32 melanomas, 129 BCCs – 114 of which were from the Witkowski 2016 dataset,
13 cSCCs and one syringoid eccrine carcinoma). Despite difference in the spectrum of included lesions, results from
the two studies were similar (Figure 13), and pooled sensitivity was 89% (95% CI 0.82% to 0.94%) and specificity 85% (95%
CI 75% to 92%).
One study from each of these two groups (Rao 2013; Witkowski 2016) provided data both for correct diagnosis of each
malignancy and for the decision to excise suspicious lesions. Figure 14 and Figure 15 demonstrate the trade-off between
higher sensitivity and lower specificity from the lower excision threshold.
4 Other lesion populations
Four evaluations of RCM in other study populations were identified. Summary characteristics of studies are provided in
#165b Reflectance confocal microscopy for the diagnosis of keratinocyte skin cancers in adults
15 / 119
Appendix 8, and forest plots and ROC plots of study data are provided in Figure 8 and Figure 9.
Two studies included lesions with a high index of suspicion for BCC. Castro 2015 included excised lesions suspicious for
BCC based on clinical and dermoscopic examination and that were amenable to RCM examination using a handheld RCM
probe (Vivascope 3000) to allow comparison with the standard approach (Vivascope 1500); 83% (45/54) of included lesions
were histological proven to be BCC. The presence of RCM lesion characteristics selected from previous studies was
assessed; however, it was not clear whether this was an image-based or in-person evaluation. Sensitivity was 100% (95% CI
92% to 100%) using the Vivascope 1500 system compared to 93% (95% CI 82% to 99%) using Vivascope 3000, and
specificity estimates were both 78% (95% CI 40% to 97%). No melanomas or cSCCs were included in this study.
Nori 2004 included 83 biopsy-confirmed BCCs and a convenience sample of non-BCC with 'range of common diagnoses';
the prevalence of BCC was 55% (83/152). Diagnosis based on images acquired using the Vivascope 1000 and based on the
presence of morphologic RCM characteristics previously investigated by the same group was compared to visual inspection
of clinical images (latter reported for only 105 of the 152 lesions). Sensitivity and specificity were both higher using RCM
(based on the presence of 3 or more RCM criteria) compared to visual inspection: sensitivity was 94% (95% CI 86% to 98%)
versus 48% (95% CI 35% to 62%) and specificity 78% (95% CI 67% to 87%) compared to 62% (95% CI 46% to 75%).
Results for the 4 included cSCCs could not be disaggregated from the benign diagnoses; no melanomas were included.
Incel 2015 examined 122 nonpigmented suspected malignant lesions or proliferative skin lesions with a vascular structure on
dermoscopic examination with the handheld Vivascope 3000 system, using selected characteristics considered to be
indicative of BCC and characteristics considered to be indicative of cSCC. The prevalence of BCC was 46% (56/122); of
cSCC was 7% (9/122); with keratoacanthoma, seborrhoeic, actinic keratosis, or Bowen's disease making up half of the
benign group (29/57). Sensitivity for the detection of BCC was 91% (95% CI 80% to 97%) and specificity 100% (95% CI 95%
to 100%). All 9 SCCs were considered test negative (i.e. not mistaken for BCCs). Sensitivity for the detection of cSCC was
82% (95% CI 48% to 98%) and specificity 96% (95% CI 91% to 99%). Similarly, no BCCs were mistaken for SCCs in this
study.
Longo 2013 included 140 clinically nodular lesions that underwent excision including 23 nodular melanomas (16%), 28 BCCs
(20%), 6 cSCC (5%), and 9 with cutaneous melanoma metastases (7.5%). An experienced dermatologist interpreted RCM
images blinded to dermoscopy using RCM ‘pattern analysis. Excluding non-evaluable results (including 1 BCC and 1 SCC),
sensitivities were 100% for detection of BCC and SCC, and specificities were 97% (95% CI 92% to 99%) for BCC and 100%
(95% CI 97% to 100%) for SCC. For the detection of any malignant lesion (excluding melanoma metastases), sensitivity was
100% (95% CI 93% to 100%) and specificity 85% (95% CI 75% to 92%).
Discussion 
Summary of main results
RCM has been evaluated in a range of study populations and using a number of different approaches to assist diagnosis.
Most of the data relate to the detection of BCC, with few studies recruiting sufficient numbers of participants with cSCC (i.e.
>= 5) to allow accuracy to be reliably estimated. Both sensitivity and specificity for the detection of BCC appeared to vary
with the spectrum of included lesions. Sensitivity was relatively low in participants with any suspicious lesion but was higher
in studies of more selected populations. Studies were generally at high or unclear risk of bias across almost all domains and
of high or unclear concern regarding applicability of the evidence, limiting the strength of conclusions that can be drawn. The
Summary of findings table 1 presents key results for the primary target conditions of BCC and cSCC.
For the detection of BCC in participants with any suspicious lesion, RCM summary sensitivity was 76% and specificity 95%.
Applying these estimates to a hypothetical cohort of 1000 lesions at the median prevalence of BCC of 12.5%, the Summary
of findings table 1 shows that RCM would miss 30 of 125 BCCs with 44 false positive diagnoses. On the evidence
observed, only one of these false positive results might be a melanoma with up to two misdiagnosed cSCCs. The
wide confidence intervals for both estimates mean that the number of BCCs missed could range from 10 to 69, and
number of false positives from 9 to 298. A single cohort of lesions with a high clinical or dermoscopic suspicion of
being melanomas was responsible for most of the variation in results (Pellacani 2014b (doc)). The other studies in this group
had sensitivities between 52% and 67% and specificities above 95%, which would correspond with numbers of BCCs missed
at the higher end of the 10 to 69 per 1000 range, and false positives at the lower end of the 9 to 298 per 1000 range (with a
corresponding reduction in the potential for melanomas being misclassified as BCCs).
RCM sensitivity was higher (94%) for the detection of BCC in participants with equivocal lesions, but with a lower specificity
of 85%. Applying these estimates to a hypothetical cohort of 1000 lesions at the median prevalence of BCC of 15%, the
Summary of findings table 1 shows that RCM would miss 9 of 150 BCCs with 128 false positive diagnoses. On the
evidence observed for equivocal lesions, there is a much greater potential for misdiagnosis of melanomas as
BCCs, with up to 19 of these false positive results potentially being melanomas. The confidence intervals around
these estimates are not as wide as for any suspicious lesion: the number of BCCs missed at this disease
prevalence could range between 3 and 32, and number of false positives from 68 to 238. The lowest sensitivity
(85%) and highest specificity (94%) in this group were produced from the cohort of non-pigmented lesions (Witkowski 2016)
as opposed to the other two studies recruiting lesions equivocal for melanoma diagnosis.
Insufficient data were available to compare RCM with visual inspection or dermoscopy or to consider the effect of using
formally developed algorithms to assist RCM diagnosis of BCC. There was however some evidence of higher sensitivity from
more experienced observers.
Data for the detection of cSCC were limited but suggest sensitivity in the range of 74 to 77% with high specificity of 92 to
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98%.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure according to patient pathway was adopted to allow test accuracy in different study
populations to be estimated, and a detailed and replicable analysis of methodologic quality was undertaken.
The main concerns for the review are a result of the small number of studies, variation in the spectrum of included
lesions, and poor reporting of primary studies, hindering the assessment of study quality and limiting the conclusions
that can be drawn from the data. Despite some evidence of high sensitivity or specificity, or both, depending on the
study population, research in the field has been dominated by a single expert group and results obtained from a
more typical range of specialists in different countries, healthcare systems, and settings are needed. Our analysis by
observer experience across algorithms and study populations lends support to the consensus that experience and
observer familiarity with the diagnostic question is a key element of any diagnostic process that requires
interpretation by the human eye (Norman 2009). Only one eligible study evaluated a formally developed algorithm to
assist RCM interpretation; however, we excluded four studies from our review that examined individual RCM
characteristics only or did not use separate training and test sets of data (Amjadi 2011; Eichert 2010; Peppelman 2015; 
Rishpon 2009). Further work in this area may be warranted.
Given these limitations, our results should be considered as exploratory rather than conclusive. Our results are in
contrast to those of other recently published systematic reviews (Xiong 2016; Edwards 2016), one of which was
conducted as part of a technology assessment report for NICE (Edwards 2016). Our review however extends the time period
searched for eligible studies from 2014 in Edwards 2016 and from 2015 in Xiong 2016, considers the impact of
different study populations and target conditions, and uses currently recommended methods for diagnostic test
accuracy systematic reviews (Deeks 2013). Xiong 2016 did not consider varying definitions of the target condition in
their primary analysis but pooled all studies regardless of detection of melanoma, BCC, or SCC. In a secondary
analysis, three studies were pooled for the detection of BCC, producing estimates of sensitivity of 91.7% (95% CI 0.87
to 0.95) and specificity of 91.3% (95% CI 0.94 to 0.96); two of the three studies with high percentages of BCC lesions
were included in our ‘other population’ analysis (Castro 2015; Nori 2004); and one was excluded from this review
due to the presentation of individual RCM features for detection of BCC rather than for an overall diagnosis (Peppelman
2013). The Edwards 2016 review did not conduct a meta-analysis, instead selecting studies considered to be more
applicable to a UK setting. Using the Castro 2015 study, which was included in our review as an ‘other lesion population’
study, economic modelling showed RCM to be a dominant strategy when used in populations with a high clinical suspicion of
being BCCs in comparison to diagnostic biopsy, whether used in lesions positive or equivocal for BCC on dermoscopy. The
potential for misdiagnosis of any melanomas or cSCCs as BCCs does not appear to have been considered.
Applicability of findings to the review question
Insufficient data were available to compare the accuracy of RCM with visual inspection or dermoscopy as planned. Similarly
a lack of data to assess the use different algorithms to aid diagnosis was identified. It is not clear how applicable the data
included in this review are regarding the routine use of RCM in a usual clinic setting as opposed to a highly specialist centre
with expert RCM observers. Data are lacking regarding specific uses of the test, for example, to confirm a clinical diagnosis
of BCC before initiation of non-surgical treatment. Most of the studies used the current version of the only commercially
available RCM system, the Vivascope 1500. The use of remote image-based diagnosis largely by RCM experts may restrict
the transferability of results to a clinical setting.
Authors' conclusions 
Implications for practice 
It is unclear whether RCM has a role in clinical practice for the diagnosis of BCC, although some studies suggest it has the
potential to improve diagnoses. There are as yet insufficient data to support its use as a tool for avoidance of diagnostic
biopsies in lesions with high clinical suspicion of BCC. In populations with a wider spectrum of lesions, there is potential for
both missed BCCs and for misclassification of benign lesions, or other malignant skin cancers such as melanoma, as BCCs.
Evidence for the detection cSCC is even more scarce; however, there is a clear suggestion that cSCCs could be missed with
RCM. Importantly, data are lacking that compare RCM to usual practice (whether with or without dermoscopy), such that the
diagnostic impact of RCM cannot be clearly estimated.
Implications for research 
Further prospective evaluation of RCM in populations with a high clinical suspicion of BCC is warranted. Research
should be conducted in a standard healthcare setting with a clearly defined and representative population of
participants with dermoscopically equivocal lesions. RCM results should be interpreted in a usual care setting by
healthcare staff representative of those who would be likely to interpret images in practice, in order to confirm the
suggested increase in accuracy over dermoscopy. A multicentre approach would allow confirmation that results can
be replicated across centres and that the technology can be implemented across a health service. Prospective
recruitment of consecutive series of participants, with test interpretation blinded to the reference standard diagnosis
and with pre-specified and clearly defined diagnostic thresholds for determining test positivity is easily achieved.
Systematic follow-up of non-excised lesions avoids over-reliance on a histological reference standard and allows
results to be more generalisable to routine clinical practice. A standardised approach to diagnosis, and clear
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identification of the level of training and experience required to achieve good results is also required. Any future
research study needs to be clear about the diagnostic pathway followed by study participants prior to study
enrolment, and should conform to the updated Standards for Reporting of Diagnostic Accuracy (STARD) guideline (Bossuyt
2015).
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For the primary objective, study populations that could not be clearly identified as either 'any suspicious lesion' or 'equivocal
lesions' were considered separately as 'other lesion' studies.
Secondary objectives have been tailored to the individual test, with three objectives added: to compare the accuracy of RCM
to dermoscopy where both tests have been evaluated in the same studies; to determine the diagnostic accuracy of individual
algorithms for RCM; and to determine the effect of observer experience.
The secondary objective has been changed from "for the detection of any skin cancer" to "for the detection of any skin
cancer in adults, where keratinocyte skin cancers make up at least 50% of included skin cancers" in order to keep the focus
on keratinocyte skin cancers for this review and in order not to replicate analyses conducted for the review of RCM for
melanoma. These changes also affect the definition of the secondary target condition in the Methods section. Heterogeneity
investigations were limited by the data available.
Population inclusion criteria amended from inclusion of adults with lesions suspicious for keratinocyte skin cancer to inclusion
of adults with lesions suspicious for any skin cancer, on the basis that studies targeting those with pigmented skin lesions or
with lesions suspicious for melanoma also report 2x2 contingency data for the detection of BCC or cSCC within these
populations. We added a requirement for a minimum of 5 benign lesions as well as 5 malignant lesions. The size threshold of
five is arbitrary. However, such small studies are unlikely to add precision to estimates of accuracy.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology); however, due to volume of evidence retrieved from database
searches and time restrictions, we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic. In terms of analysis, restriction
to analysis of per patient data was not performed due to lack of data. Sensitivity analyses were not performed as planned
due to lack of data.
We intended to analyse studies separately according to in-person and image-based assessments; however, we were unable
to do so due to lack of data.
Studies using cross-validation, such as 'leave-one-out’ cross-validation were excluded rather than included as these methods
are not sufficiently robust and are likely to produce unrealistic estimates of test accuracy.
To improve clarity of methods and to allow inclusion of studies presenting simple algorithms consisting of lesion
characteristics that had previously been suggested as associated with BCC or cSCC:, this text from the protocol, “We
will include studies developing new algorithms or methods of diagnosis (i.e. derivation studies) if they use a separate
independent ’test set’ of participants or images to evaluate the new approach.We will also include studies using other
forms of cross validation, such as ’leave-one-out’ cross-validation (Efron 1983). We will note for future reference (but not
extract) any data on the accuracy of lesion characteristics individually, e.g. the presence or absence of a pigment network or
detection of asymmetry”, has been replaced with
"Studies developing new algorithms or methods of diagnosis (i.e. derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with BCC or cSCC and the study
reported accuracy based on the presence or absence of particular combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no
separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no
overall diagnosis of malignancy."
Although we extracted any reporting of special interest or accreditation in skin cancer according to observer expertise, we
were unable to analyse the effect on accuracy due to lack of data.
As per the change to secondary objectives, this text from the protocol "For our secondary objective, the target condition will
include any skin lesion requiring excision. We will include studies reporting data for keratinocyte skin cancer combined, and
not differentiated according to BCC or cSCC, in this analysis, along with any melanoma or rare skin cancer (e.g. Merkel or
amelanotic melanoma) that may be detected. We will not consider in situ cancers or actinic keratosis as disease-positive"
has been changed to "An additional definition of the target condition was considered in secondary analysis, the detection of:
any skin cancer, including BCC, cSCC, melanoma or any rare skin cancer (e.g. Merkel cell cancer), as long as skin
cancers other than melanoma made up more than 50% of the disease positive group. Data from studies in which
melanoma accounted for more than 50% of skin cancers were included in the review of RCM for the diagnosis of
melanoma (Dinnes 2018a)."
Added the following as possible sources of heterogeneity in Appendix 2:
patient population: Primary /secondary / specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
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inclusion of multiple lesions per participant
Published notes 
Characteristics of studies
Characteristics of included studies 
Castro 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection: Not reported
Country: Brazil and USA
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients recruited were those
presenting with one or more skin lesions that were highly
suspicious for BCC based on clinical and dermoscopic
examination. All lesions underwent biopsy.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Clinical or dermatoscopic suspicion, or both
Setting for prior testing: Unspecified
Exclusion criteria: Poor quality index test image; From
discussion: "HH-RCM imaging was successfully
performed in all lesions in which imaging was attempted,
while TWP-RCM was technically applicable in only 59%
of lesions in which imaging was attempted."
Sample size (patients): No. eligible: 73
Sample size (lesions): No. eligible: 92. No. included: 54
Participant characteristics: Mean age 65y (30-89y).
Fitzpatrick phototype: 24 patients with type II; 8 patients
with type III
Lesion characteristics: Site reported for BCCs only -
Head/Neck: 9, Trunk: 26, Upper limbs/shoulder: 4,
Lower limbs/hip: 6
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM). Vivascope 3000; using two different ways of assessment
using hand-held (HH-RCM) and traditional wide-probe (TWP-RCM)
No algorithm. Previously-published RCM criteria assessed (cites Agero 2006, Nori 2004, Guitera 2012)
and selected criteria chosen
Method of diagnosis: Not clearly reported; may be in person "All examinations, including clinical,
dermoscopic and RCM imaging, were made by a dermatologist experienced with RCM examination
(RPRC) with supervision by a skin cancer expert (GGR or HR)." However, also states that "All RCM
images were evaluated jointly by two readers blinded to the results of the histopathological
examination." Not clear whether this was undertaken at the time of RCM examination or subsequently.
Prior test data: Clinical examination and dermoscopy "All examinations, including clinical, dermoscopic
and RCM imaging, were made by a dermatologist experienced with RCM examination (RPRC) with
supervision by a skin cancer expert (GGR or HR)."
Diagnostic threshold: ≥3 RCM criteria present,
Diagnosis based on: Consensus (2 observers); (n= 2)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users (not stated but both observers co-authored
studies developing RCM)
Other detail: attempted imaging with HH-RCM and TWP-RCM using a standardized protocol, however,
TWP-RCM imaging is restricted to anatomic locations that allow contact and is not feasible in some
anatomic locations such as the eyelids
Derivation aspect to study: Images were evaluated for the presence of previously-published RCM
criteria for identification of BCC (2,6,7); Approach to selection of characteristics indicative of skin
cancer was not described.
Characteristics selected: "at least one of the criteria had to be the presence of ‘dark silhouettes’ or
‘bright tumor islands’; these latter criteria denote the presence of neoplastic aggregates of BCC and
hence need to be observed in all cases identified as BCC by RCM." Additional criteria assessed were:
‘streaming’ polarization of nuclei in neoplastic aggregates along the same axis of orientation;
‘peripheral palisading’ of nuclei at the tumor islands’ periphery;
dark ‘peritumoral clefts’ around the tumor islands;
fibrotic stroma with ‘thickened collagen bundles’;
dilated and tortuous ‘linear blood vessels’ and ‘coiled blood vessels’;
‘bright dendritic structures’ within tumor islands; and
‘bright round cells’ in the stroma.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
#165b Reflectance confocal microscopy for the diagnosis of keratinocyte skin cancers in adults
21 / 119
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: No further details provided
Disease positive: 45 BCCs; Disease
negative: 9
Target condition (Final diagnoses)
BCC: 45
'Benign' diagnoses: 9
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Imaging with both
TWP-RCM and HH-RCM was attempted
in92 lesions from 73 patients; however, 38 of
the lesions (41%),mostly facial, were
excluded as they were only accessible to
HH-RCM imaging.
Time interval to reference test: Not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Curchin 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Jan 2010 to May
2010
Country: Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients from Dermatology
department’s minor excision booking list; not further
described
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. included: 42
Sample size (lesions): No. included: 50
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Reflectance confocal microscopy (RCM). Vivascope 1500; RCM score (Pellacani 2007) and LM
score for suspected lentigo maligna of the face (Guitera 2010)
Method of diagnosis: In person diagnosis
Prior test data: Dermoscopy "dermoscopic and RCM images were aligned over the top of each other
so that correlation between the two could be made"
Diagnostic threshold: For melanoma - RCM score: >=3; threshold for LM score for suspected lentigo
maligna of the face was not described (Guitera 2010). Observer diagnosis for SCC/BCC; RCM
features listed
Diagnosis based on: Single observer; (n= 1?)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Low experience / novice users; analysis was performed by a novice to
RCM analysis after completing a RCM analysis course in Modena, Italy.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: No further details provided
Disease positive: 21; Disease negative: 29
Target condition (Final diagnoses)
Melanoma (invasive): 12; Melanoma (in
situ): 1; BCC: 9; cSCC: 6 (includes SK or
AK, or both)
'Benign' diagnoses: 23
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Farnetani 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series; series of cases
consecutively and retrospectively selected by an
expert dermoscopist for a web-based inter-
observer reliability study
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: not reported
Country: Italy (lesion image acquistion);
Observers were located in the US (3), Europe (4),
Australia (1) and Israel (1).
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Diagnostically equivocal lesions
excised due to clinical or dermoscopic suspicion of
melanoma, where a specific clinical and
dermoscopic diagnosis could not be rendered with
certainty. Lesions selected by an expert
dermoscopist blinded to final diagnosis
Setting: Secondary (general dermatology); All
included RCM images were collected at the
Department of Dermatology of the University of
Modena and ReggioEmilia (Modena, Italy),
Prior testing: Clinical or dermatoscopic suspicion, or
both
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Poor quality index test image; "No
additional selection criteria were considered in case
selection such as the presence or lack of
pigmentation, diameter, elevation, or other clinical or
dermoscopic attribute"
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 100
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Reflectance confocal microscopy (RCM). Vivascope 1500; No algorithm - evaluators completed a
‘pattern description’ (presence/absence of a number of RCM features)
Method of diagnosis: Confocal images (remote); 3 RCM mosaic images presented per lesion
Prior test data: Dermoscopy "Each case for evaluation had a high-resolution dermoscopic image
obtained with a dermoscopic lens that was attached to a digital camera." "No additional clinical
information (eg, age and melanoma or lesion history) was provided to evaluators."
Diagnostic threshold: Evaluators completed a ‘pattern description’ (presence/absence of a number of
RCM features) and gave an overall diagnosis of malignant (melanoma or BCC) or benign.
Diagnosis based on: Single observer (results presented for each of 9 observers); Consensus (≥5 of 9
evaluators); Average (across 9 observers and across 6 more experienced and 3 less experienced
observers); (n= 9)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Low experience / novice users (3 with <3 years RCM experience). High
experience /‘Expert’ users (6 with >=3 years RCM experience)
Derivation aspect to study: In addition to pattern analysis described above, discriminant analysis was
used to identified RCM features independently associated with malignancy, melanoma and BCC.
Three of 6 discriminatory RCM features were more frequently observed in melanoma: the presence of
pagetoid cells, the presence of atypical cells at the DEJ, and irregular epidermal architecture; 3 of 6
discriminatory RCM features were more frequently observed in BCCs: basaloid cord–like structures,
presence of ulceration, and a specific DEJ pattern. Accuracy was not estimated for combinations of
these particular features
Reflectance confocal microscopy
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: No further details provided
Disease positive: 35; Disease negative: 65
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not
reported): 20; BCC: 15
Seborrheic keratosis: 7; Other: 55
melanocytic nevi, 3 actinic keratoses
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Excised lesions only
included
Time interval to reference test: not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Guitera 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported
Period of data collection: NR
Country: Australia and Italy
Test set derived: randomly split into
training and test sets
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive patients presenting or
found with suspicious lesions, including all macules of
the face and neck suspicious for lentigo maligna, and
which would be subjected to biopsy or excision to rule
out an epithelial tumor or an MM following conventional
clinical and dermoscopy diagnosis and with lesion
location amenable to RCM; described as predominantly
melanocytic or suspicious for BCC
Setting: Mixed, lesions recruited from Modena (general
dermatology) and Sydney (skin cancer/pigmented
lesions clinic)
Prior testing: Clinical or dermatoscopic suspicion, or both
Exclusion criteria: Location/site of lesion keratotic, sole,
and palm lesions were excluded
Sample size (patients): No. eligible: 663
Sample size (lesions): No. eligible: 710 / No included:
356 in test set, 253 melanocytic
Participant characteristics: Median age (full sample): 53,
IQR 39 to 66 (for full sample), Range: 6-90; Male: 354;
53.4% (of full sample)
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM): RCM score and Segura algorithm; also derived own
independently significant features for MM and BCC.
Vivascope 1500
Method of diagnosis: Confocal images (remote)
Prior test data: Lesion site or patient age only, or both: "RCM features were described by two expert
observers (GP and PG), blinded from any clinical information, dermoscopy, and clinical aspects, but
not for the location and age of the patient"
Diagnostic threshold: Two established algorithms assessed: Pellacani scoring system for
melanoma (Pellacani 2007), score >3; and Segura 2-step algorithm (Segura 2009), score of zero; own
new two step model identified 7 independently significant features for MM (assume presence of any
one indicated T+):
cerebriform nests,
atypical cobblestone pattern with small nucleated cells in the epidermis,
marked cytological atypia,
pagetoid cells,
disarranged epidermal layer with no honey comb,
large inter-papillae spaces filled with honeycomb,
dense nest.
8 independently significant features for BCC:
polarized in the honeycomb,
linear telangiectasia-like horizontal vessels,
basaloid cord or nodule,
epidermal shadow,
convoluted glomerular-like vessels,
non-visible papillae,
cerebriform nests,
disarray of the epidermal layer.
Derivation aspect to study: 
Lesion characteristics assessed a series of 48 features, corresponding to previous
observations (Pellacani 2007; Guitera 2009), and new descriptors were considered at three different
depth levels. Descriptions and definitions provided.
Selection of characteristics indicative of skin cancer by multivariate discriminant analysis performed on
the training set.
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: High experience /‘Expert’ users
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: not further described; full sample Disease
positive: 335 / disease negative 375
Target condition (Final diagnoses): Test set only
Melanoma (in situ and invasive, or not reported):
105; BCC: 52; cSCC: 9
Benign nevus 132; Spitz nevus 16; actinic keratosis
8; 31 benign macule of the face and 3
dermatofibroma
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
No exclusions
Imaged prior to biopsy
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Incel 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective (assumed);
"Written consent was obtained from all
participants before enrolment."
Period of data collection: NR
Country: Turkey
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with nonpigmented suspected
tumoral lesions or proliferative skin lesions and with a
vascular structure on dermoscopic examination
Setting: Secondary (not further described) Istanbul
Training and Research Hospital
Prior testing: Clinical or dermatoscopic suspicion, or both
- all participants underwent clinical evaluations "following
guidelines of the visual inspection and diagnosis of
nonpigmented skin tumor"; those with a vascular
structure on dermoscopic examination underwent RCM
Setting for prior testing: Secondary (general
dermatology); Specialist unit (skin cancer/pigmented
lesions clinic)
Exclusion criteria: prominent hyperkeratosis; history of
significant other skin disease, kidney, liver, heart
disease, surgery, or invasive procedure on the
localization of tumor in the last 6 months, sunbathing or
indoor tanning in the last 3 months, and subjects who
are receiving therapy that has angiogenic effects such
as systemic/topical steroids
Sample size (patients): No. included: 114
Sample size (lesions): No. included: 122
Participant characteristics: Median age 61y, range
18-87y; Male: 57%
Lesion characteristics: Site - head and neck (76.2%),
extremities (10.2%), back, abdomen, and chest (13.6%).
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Reflectance confocal microscopy (RCM): Characteristics from previous studies selected to assist
correct diagnosis of different lesion types; also assessed vascularity of lesions using RCM but this did
not inform diagnosis. Vivascope 3000
Method of diagnosis: Unclear; Images of first 60 lesions subjected to blinded evaluation by 2 observers
to identify vascular morphology; unclear whether overall diagnoses reported were based on images or
in person assessments
Prior test data: Unclear
Diagnostic threshold: Characteristics listed for BCC included: Dark silhouettes in dermis, Bright tumour
islands at DEJ and in the dermis; Cleft-like dark areas; Dendritic cells, Bright rond cells, Canalicular
vessels. Characteristics listed for SCC included: Refractile squam/crust in stratum corneum and
nucleated cells with dark center (parakeratotic)
cells; Atypical honeycomb pattern, disarranged pattern at stratum granulosum layer; Large, round,
nucleated cells at the granular layer (dyskeratotic cells); Dendritic cells at the granular layer and small
edged papillae at DEJ; Dendritic cells (referenced to Malvehy 2012, Eichert 2010, Ahlgrimm-Siess
2010, Röwert-Huber 2007, Ahlgrimm-Siess 2011)
Derivation aspect to study: Study assessed assessed vascularity of lesions with RCM but diagnoses of
each lesion type reportedly based on above characteristics.
Diagnosis based on: NR
Observer qualifications: NR
Experience in practice: NR
Experience with index test: NR
Reflectance confocal microscopy
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis alone
Details: Clinically, dermoscopically, and confocally
suspected malignant lesions, recurrent, and therapy
resistant lesions were excised; benign appearing but
suspected lesions were punch biopsied. Formalin fixed
paraffin-embedded tissue sections were stained with
hematoxylin–eosin. Histopathological examination was
conventionally operated by light microscopy
Target condition (Final diagnoses): 
BCC: 56; cSCC: 9
Keratoacanthoma 3; Sebhorrheic keratosis 11; Actinic
keratosis 8; Bowen's disease 7; and 24 other
nonpigmented tumors that included sebaceous
hyperplasia (4), eccrine poroma (4), pyogenic granuloma
(3), amelanotic melanoma (2), sebaceous adenoma (2),
trichilemmoma (2), warty dyskeratoma (1), pilomatrixoma
(1), kaposi sarcoma (1), fibrohistiocytic tumor (1), eccrine
spiradenoma (1), and eccrine porocarcinoma (1).
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index to reference interval: appears
consecutive "Biopsy was taken for routine
histology from selected patients, and was
examined with RCM."
No exclusions were reported
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
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Notes
Notes -
 
Longo 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: NR
Country: Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Clinically nodular lesions (defined as
cutaneous palpable/superficial seated lesions and not
subcutaneous ones) that underwent excision
Setting: Secondary (general dermatology); Specialist unit
(skin cancer/pigmented lesions clinic)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general dermatology);
Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported (not evaluable and non
specific RCM results excluded; see below)
Sample size (patients): No. included: 140
Sample size (lesions): No. included: 140
Participant characteristics: Mean age 50 years (SD 19.7).
Male: 64; 45.7%
Lesion characteristics: All clinically nodular; Site - 'most' on
the trunk; dermatofibroma mainly located on extremities.
Mean thickness 2.16 mm (SD 82); 23 'pure' nodular
melanomas
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM). Model NR; likely Vivascope 1500. No algorithm - reports
observer diagnosis and independently significant features
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used; blinded to dermoscopic image
Diagnostic threshold: A diagnosis was formulated based on 'RCM pattern analysis' (Longo 2011; 
Pellacani 2007; and several others cited)
Diagnosis based on: Single observer (n= 1)
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; 5 years’ experience in RCM and therefore
presumably in practice
Experience with index test: High experience /‘Expert’ users; 5 years’ experience in RCM
Derivation aspect to study: Main study data included relate to observers interpretation of RCM
characteristics and diagnostic classification. Univariate and then multivariate discriminant analysis was
also performed to identify independently significant RCM criteria (total of 36 assessed) for NM+Mets
vs. all other diagnoses, BCC vs. all other diagnoses, SCC vs. all other diagnoses. The data presented
however relate to only 130 lesions, and the melanoma metastases cannot be separated from the
nodular melanoma, therefore melanoma data not included
Characteristics selected for nodular melanoma or melanoma mets were: widespread pagetoid
distribution ; many atypical cells; and cerebriform nests. Characteristics selected for BCC were: tumour
islands ; cauliflower architecture; bright filaments within the tumour islands; and presence of bright
collagen. Not clearly reported for SCC
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: No further details provided
Disease positive: 66; Disease negative: 57
Target condition (Final diagnoses) 
Melanoma (invasive): 23 nodular; BCC: 28;
cSCC: 6; Other malignant: 9 melanoma
metastases
Sebhorrheic keratosis: 14; Benign naevus:
32; (14 compound, 8 intradermal, 3 blue
naevi, 7 Spitz naevi); Other: 5 vascular and 6
other benign lesions
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 8 not evaluable and 3
‘nonspecific’ RCM results reported (appear to be
excluded from derivation of independently
significant characteristics)
Not evaluable: lesions where all the three levels
(epidermis, DEJ and upper dermis) were not
explorable for any reason that hampered the
collection of quality images or the exploration of
DEJ/superficial dermis. Nonspecific: lesions where
a diagnosis could not be formulated, despite the
possibility of exploring all three levels, because of
the impossibility of recognizing diagnostic features
with enough confidence.
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Nori 2004
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control; appears to be case-
control type design sampling BCC and non-BCC
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: 2 years - date range
not specified
Country: US and Spain
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Biopsy-confirmed BCC and
convenience sample of non-BCC with 'range of
common diagnoses' ( only 7 of the 69 non-BCC had
BCC on the list of possible differential diagnoses); of
these 105 images were selected for clinical
assessment based on superior clinical image quality
Setting: Secondary (general dermatology) Division
of Dermatology, Loma Linda Uni Med School;
Dermatology Servive, Madrid, Spain; Private care
(Dermatology and Dermatologic surgery private
practice); Wellmann Laboratories of Photomedicine,
Massachusetts General Hospital
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. included: 145
Sample size (lesions): No. included: 152; 105 in VI
analysis
Participant characteristics: Male: 98; 64%
Lesion characteristics: Lesion site: Face/Ears: 35%;
Trunk: 13%; Limbs: Extremities 45%; Back 7%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Diagnostic threshold: Not reported. Lesions assigned to: High probability (BCC until proven otherwise),
medium probability (would biopsy to rule out BCC), and low probability (no biopsy needed).
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
#
Reflectance confocal microscopy (RCM). Vivascope 1000 (plus prototype device built in Wellman
Laboratories (n=20)). No algorithm; selected characteristics assessed (referenced to Gonzalez 2002)
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used; images from all 152 lesions was retrospectively analyzed
in a blinded fashion
Diagnostic threshold: >=2, 3, 4 or 5 present of 5 features selected based on prior study by same
authors (?elongated monomorphic basaloid nuclei; polarization of these nuclei along the same axis of
orientation; prominent inflammatory infiltrate; increased dermal vasculature; pleomorphism of the
overlying epidermis indicative of actinic changes.)
Diagnosis based on: Single observer (n= 1)
Observer qualifications: 'Novice confocal reviewer' reviewed all images
Experience in practice: Not described
Experience with index test: Low experience / novice users; novice confocal reviewer
Other detail The images produced by Vivascope 1000 and prototype device reportedly similar, with no
measurable differences between them.
Derivation aspect to study: The 5 criteria were chosen as they were "easily and unambiguously
detected by non dermatopathologists and our novice reviewer so that the applicability of our results
would be useful to the dermatology community as a whole."
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis plus other
Details: 15 lesions were not biopsied (eg,
lesions like seborrheic keratosis) because
the clinical diagnosis was considered
diagnostic
Histology: Disease positive: 83; Disease
negative: 54
Expert opinion; Disease positive: 0; Disease
negative: 15
Target condition (Final diagnoses) 
BCC: 83; 58 in VI analysis; cSCC: 4
'Benign' diagnoses: 65
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Unclear
Was the minimum clinical follow-up after application of index test(s) adequate?
If more than one algorithm evaluated for the same test, was the interval between
application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Pellacani 2014a (cons)
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series (consultation group
documented here)
Data collection: Prospective
Period of data collection: January 2010 to
December 2010
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients requesting a mole check or
with suspicion of melanoma who were referred to
pigmented lesion clinic and who were then found to have
atypical lesions on dermoscopy. Those in whom
diagnosis could not be determined on dermoscopy were
referred for an 'outcome decision' (consultation group).
Patients were referred on the basis of both urgent
access (melanoma suspected in a single lesion by GP or
other dermatologist) and scheduled access (referred for
dermoscopy and total body examination).
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Dermatoscopic suspicion in all cases. All
patients underwent dermoscopy in the PLC; those with
dermoscopically atypical lesions were referred for RCM,
either to document a lesion already selected for excision
(documentation group, reported in Pellacani 2014b
(doc)) or for an 'outcome decision' (consultation group),
i.e. diagnosis could not be determined on dermoscopy
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Clinically or dermatoscopically clear-
cut epithelial tumours, or both, were not enrolled; Poor
quality index test image - In nine cases RCM could not
be performed (five RCM documentation and four RCM
consultation) due to the presence of artefacts,
hyperkeratosis, or ulcerations, impeding imaging.
Sample size (patients): No. eligible: 1005 examined with
dermoscopy; No. included: 252 referred for RCM
consultation
Sample size (lesions): No. eligible: NR; No. included:
308 for RCM documentation
Participant characteristics: Median age 41.7 (IQR 31.9,
52.1); For all referred patients (n=1005): 443 male
(44%); Consultation group only: History of
melanoma/skin cancer 23 (7%); Family history of
melanoma 30 (10%). Fitzpatrick phototype I to II: 150
(49%); Type III to IV 116 (38%)
Lesion characteristics: Lesion site (full sample)
Head/Neck: 9%; Trunk: 59%; Upper limbs/shoulder:
12%; Lower limbs/hip: 20%
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
Reflectance confocal microscopy (RCM). RCM score
Vivascope 1500
Method of diagnosis: In person
Prior test data: Patients were "referred to confocal unit"; confocal reader was blinded to the patient
pathway and aware that lesions were dermoscopically atypical for ‘RCM documentation’ or for ‘RCM
consultation’.
Diagnostic threshold: Not reported, Pellacani 2005 cited
Diagnosis based on: Single observer (n=1)
Observer qualifications: Dermatologist (assumed; patients were "referred to confocal unit")
Experience in practice: Not described
Experience with index test: Not described but 'confocal unit' described
Other detail Any other detail Dermatoscopy examinations were conducted using the Dermlite HR
(3Gen LLC, San Juan Capistrano, CA, U.S.A.). Lesions that were scheduled for digital monitoring
were also acquired by means of FotoFinder (TeachScreen GmbH, Bad Birnbach, Germany) using 20-
fold magnification.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
plus FU and cancer registry follow-up
Histology (not further described): 81 (consultation
group); overall dataset - 292 excised (see Pellacani
2014b (doc)]
Clinical FU: 227. 28 of which were subsequently
excised because of observed dermatoscopic
changes (all benign). Most non excised lesions
(89.4% 178/199) were followed up for 1 year; the
others were lost at the 1-year follow-up.
Cancer registry FU: Those lost to clinical follow-up
were checked on the tumour registry; no melanomas
were diagnosed in patients scheduled for follow-up
after baseline examinations.
Target condition (Final diagnoses) 
Melanoma (invasive): 13; Melanoma (in situ): 9;
BCC: 19; 1 melanoma metastasis
Clark naevus 71; Spitz nevus 5; solar lentigo,
seborrhoeic keratosis
or lichen planus-like keratosis 0; other benign 207 (8
with histological diagnosis (25 Clark naevi, two Spitz
naevi and one benign nonmelanocytic lesion) and
199 benign on FU)
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of
the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 9 excluded due to
RCM failure
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?Yes
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Pellacani 2014b (doc)
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series (documentation group
described here)
Data collection: Prospective
Period of data collection: January 2010 to
December 2010
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients requesting a mole check or
with suspicion of melanoma who were referred to
pigmented lesion clinic and who were then found to have
atypical lesions on dermoscopy. Those in whom excision
was required on dermoscopy were referred for RCM
documentation (documentation group). Patients were
referred on the basis of both urgent access (melanoma
suspected in a single lesion by GP or other
dermatologist) and scheduled access (referred for
dermoscopy and total body examination).
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Dermatoscopic suspicion in all cases. All
patients underwent dermoscopy in the PLC; those with
dermoscopically atypical lesions were referred for RCM,
either to document a lesion already selected for excision
(documentation group, as reported here) or for an
'outcome decision' (consultation group, reported in
Pellacani 2014a (cons)), i.e. diagnosis could not be
determined on dermoscopy.
Setting for prior testing: Specialist unit (skin
cancer/pigmented lesions clinic)
Exclusion criteria: Clinically or dermatoscopically clear-
cut epithelial tumours, or both, were not enrolled; Poor
quality index test image - In nine cases RCM could not
be performed (five RCM documentation and four RCM
consultation) due to the presence of artefacts,
hyperkeratosis, or ulcerations, impeding imaging.
Sample size (patients): No. eligible: 1005 examined with
dermoscopy; No. included: 171 referred for RCM
documentation
Sample size (lesions): No. eligible: NR; No. included:
183 for RCM documentation
Participant characteristics: Median age 41.2 (IQR 35,
63); For all referred patients (n=1005): 443 male (44%);
History of melanoma/skin cancer 8 (5%); Family history
of melanoma 13 (8%). Fitzpatrick phototype I to II: 99
(58%); Type III to IV 72 (42%)
Lesion characteristics: Lesion site (full sample)
Head/Neck: 9%; Trunk: 59%; Upper limbs/shoulder:
12%; Lower limbs/hip: 20%
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
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Index tests
Reflectance confocal microscopy (RCM). RCM score
Vivascope 1500
Method of diagnosis: In person
Prior test data: Patients were "referred to confocal unit"; confocal reader was blinded to the patient
pathway and aware that lesions were dermoscopically atypical for ‘RCM documentation’ or for ‘RCM
consultation’.
Diagnostic threshold: Not reported Pellacani 2005 cited
Diagnosis based on: Single observer (n=1)
Observer qualifications: Dermatologist (assumed; patients were "referred to confocal unit")
Experience in practice: Not described
Experience with index test: Not described but 'confocal unit' described
Other detail Any other detail Dermatoscopy examinations were conducted using the Dermlite HR
(3Gen LLC, San Juan Capistrano, CA, U.S.A.). Lesions that were scheduled for digital monitoring
were also acquired by means of FotoFinder (TeachScreen GmbH, Bad Birnbach, Germany) using 20-
fold magnification.
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histology alone for
documentation group; 227 from consultation group were
referred for follow-up (see Pellacani 2014a (cons))
Target condition (Final diagnoses) 
Melanoma (invasive): 13; Melanoma (in situ): 9; BCC:
19; 1 melanoma metastasis
Clark naevus 121; Spitz nevus 8; solar lentigo,
seborrhoeic keratosis or lichen planus-like keratosis 7;
other benign 5 (haemosiderotic dermatofibroma,
xanthogranuloma, viral wart and two nonspecific
inflammatory dermatoses)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 9 excluded due to
RCM failure
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s) adequate?Yes
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Rao 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported Appear to be
prospective but not explicitly stated
Period of data collection: Jun 2010-Sep
2011
Country: US
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All lesions removed for cosmetic or
medical reasons that were imaged using a confocal
scanning microscope
Setting: Secondary (general dermatology) Based on
author institutions
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. eligible: 340; No.
included: 334
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
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Index tests
Reflectance confocal microscopy (RCM). Vivascope 1500. No algorithm; Overall diagnosis
Method of diagnosis: In person diagnosis US (reader 1; less experienced)
Confocal images (remote) Modena, Italy; Reader 2 (more experienced)
Prior test data: For image based "diagnosis was based on the dermoscopic image and confocal
microscopy evaluation before excision."
Diagnostic threshold: Not reported; Observers gave diagnosis and excise decision (no further details)
Diagnosis based on: Single observer (n= 2)
Observer qualifications: Not reported; Presume dermatologists
Experience in practice: Not described
Experience with index test: Low experience / novice users Reader 1 (US) had 1 year of experience at
the beginning of the study; High experience /‘Expert’ users Reader 2 (Italy) had over 9 years of
experience with RCM.
Other detail Images were sent via Vivanet (CaliberID, Rochester, NY), a Health Insurance Portability
and Accountability Act-compliant server.15
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: No further details provided
Disease positive: 78; Disease negative: 256
Target condition (Final diagnoses) 
Melanoma (invasive): 8; Melanoma (in situ);
1; BCC: 27; cSCC: 42
Benign nevi 176; seborrhoeic keratosis 22;
actinic keratosis 24; other 23
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: 6 described as
excluded because of insufficient information.
Furthermore 318/334 reported for Reader 1
and 323/334 reported for Reader 2
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Notes
Notes -
 
Witkowski 2016
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: January 2009–2011
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive clinically equivocal ‘pink’
cutaneous lesions with absent pigmentation or containing less
than 10% pigment and absence of pigment network. All lesions
were excised at first visit or follow-up video dermoscopy control
visit and had available digital dermoscopy images and a
complete standard set of RCM images, with histopathology
reports
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Unequivocal appearance/diagnosis benign
diagnosis made with high confidence; lack of histological report
as a result of the lesion not being excised
Sample size (patients): NR
Sample size (lesions): No. eligible: 3869 consecutive cases
were reviewed; No. included: 260
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting
appropriate? Yes
Did the study avoid including participants with multiple
lesions? Unclear
Are there concerns that the included patients and setting do
not match the review question? Unclear
Index Test
Index tests
Dermoscopy No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Not described in detail, but accuracy presented for two diagnostic decisions:
correct diagnosis (of BCC, MM and SCC) and correct management decision (excise or not)
Diagnosis based on: Single observer (n = 2; one reader evaluated only dermoscopic images while the
second reader evaluated RCM images)
Observer qualifications: Not reported; likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Reflectance confocal microscopy (RCM) Vivascope 1500; No algorithm - Overall diagnosis
Method of diagnosis: Confocal images (remote)
Prior test data: No further information used "The first reader (JL) evaluated only dermoscopic images
while the second reader (AW) evaluated RCM images."
Diagnostic threshold: Not reported. Not described in detail, but accuracy presented for two diagnostic
decisions: correct diagnosis (of BCC, MM and SCC) and correct management decision (excise or not)
Diagnosis based on: Single observer (n= 1)
Observers as described above
Reflectance confocal microscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis alone
Details: No further details provided
Disease positive: 140; Disease negative: 120
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 12;
BCC: 114; cSCC: 13; 1 syringoid eccrine carcinoma
Sebhorrheic keratosis plus other: 25 (solar
lentigo/seborrheic keratosis/lichen planus-like keratosis/
actinic keratosis); 47 nevi; 6 spitz nevi; 18
dermatofibromas (DF), 4 vascula rlesions, and 20 other
type benign lesions (1 clear cell acanthoma, 1 discoid
lupus, 10 inflammatory lesions, 1 perivascular
hyperplasia, 4 granulomatous hyperacanathosis
reactions, 1 papulous fibrosis, 1 eccrine poroma,and 1
eczematous lesion).
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Around 357 cases were
excluded due to the lack of a histopathology
report, as a result of the lesion not being excised,
or a benign diagnosis was made with high
confidence.
Time interval to reference test: not reported
Time interval between index test(s): not reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Was the minimum clinical follow-up after application of index test(s)
adequate?
If more than one algorithm evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Footnotes
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Characteristics of excluded studies 
Agero 2006
Reason for exclusion EXCLUDE on sample size
only 5 lesions
 
Ahlgrimm-Siess 2010
Reason for exclusion EXCLUDE on study population; BCC only
EXCLUDE on sample size; only 2 cases
 
Ahlgrimm-Siess 2011
Reason for exclusion EXCLUDE on study population; SCC only
EXCLUDE on sample size; only 2 cases
 
Alarcon 2014
Reason for exclusion EXCLUDE on sample size; target condition (eligible for melanoma review only)
 
Amjadi 2011
Reason for exclusion EXCLUDE on target population Includes only BCC (82)/SCC (48) and 8 AK/SK
lesions; primary aim appears to be to differentiate BCC and SCC despite describing
inclusion of clinically difficult to diagnose non-pigmented lesions.
EXCLUDE on derivation study
 
Bassoli 2012
Reason for exclusion EXCLUDE on target condition
The aim of this study was to identify criteria for specific diagnosis of LPLK using in vivo
RCM.
 
Benati 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Braga 2009
Reason for exclusion EXCLUDE on sample size
case reports
 
Carrera 2015
Reason for exclusion EXCLUDE not a primary study
 
de Carvalho 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
de Carvalho 2016
Reason for exclusion EXCLUDE on target condition
EXCLUDE on sample size
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Edwards 2016
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Eichert 2010
Reason for exclusion EXCLUDE on individual lesion characteristics; looks at accuracy of previously
identified RCM features for melanoma, BCC and SCC in a cohort of 100 lesions but
does not give accuracy for overall diagnosis of each group.
 
Ferrari 2015
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Figueroa Silva 2016
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Gareau 2009
Reason for exclusion EXCLUDE on study population
Only BCC cases 
 
Gerger 2005
Reason for exclusion EXCLUDE on reference standard
only 1/3 of disease negative group had adequate ref test
EXCLUDE duplicate or related publication; data reported as training set in Koller 2011
(#860)
 
Gerger 2006
Reason for exclusion EXCLUDE on reference standard
Only 30/120 benign were excised (30/90 benign nevi and 0/30 SK)
 
Gerger 2008
Reason for exclusion EXCLUDE on reference standard
all MMs were excised plus 14/50 benign; remainder diagnosed on clinical/dermoscopic
criteria
 
Giambrone 2015
Reason for exclusion EXCLUDE on target condition
EXCLUDE but contact authors
they do not give information on the target condition-only state malignant/benign
cutaneous lesions??? Contacted 8-5-17
 
Gill 2014
Reason for exclusion EXCLUDE if derivation study; looking for correlation with histological features
EXCLUDE on 2x2 data; Looks at correlation between RCM features and histological
features; not test accuracy
EXCLUDE duplicate or related publication; Same lesions reportedly included in 
Pellacani 2012
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Gonzalez 2002
Reason for exclusion EXCLUDE on population includes only BCC
 
Gonzalez 2013
Reason for exclusion EXCLUDE not a primary study
 
Guida 2015
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Guitera 2009
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Guitera 2010
Reason for exclusion EXCLUDE on target condition; only looking at LM and not LMM
 
Guitera 2013
Reason for exclusion EXCLUDE on study population; LM and LMM only
EXCLUDE on target condition; data only available for LM
EXCLUDE on 2x2 data
 
Haenssle 2006
Reason for exclusion EXCLUDE on index test; surveillance study estimating accuracy of different
approaches to follow-up
 
Hennessy 2010
Reason for exclusion EXCLUDE on 2x2 data
 
Hofmann-Wellenhof 2008
Reason for exclusion EXCLUDE on reference standard; includes 70 melanocytic lesions - 20 MM (all
histologically verified); 70 benign naevi (28% histologically verified, and the rest
diagnosed with dermoscopy only). 
 
Hoogedoorn 2014
Reason for exclusion EXCLUDE conference abstract
 
Hoogedoorn 2015
Reason for exclusion EXCLUDE on sample size
 
Humphrey 2006
Reason for exclusion EXCLUDE on study population
EXCLUDE as derivation study - assesses lesion vascularity
 
Kadouch 2015
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Reason for exclusion systematic review
 
Kadouch 2015a
Reason for exclusion EXCLUDE not a primary study
clinical trial protocol
 
Koller 2011
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Kose 2014
Reason for exclusion EXCLUDE not a test accuracy study
EXCLUDE on 2x2 data
 
Langley 2001
Reason for exclusion EXCLUDE on 2x2
EXCLUDE but contact authors; contact authors for RCM 2x2 data can only get 2x2 for
clinical diagnosis 
 
Langley 2006
Reason for exclusion EXCLUDE on sample size
 
Langley 2007
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Losi 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Lovatto 2015
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Maier 2013
Reason for exclusion EXCLUDE on study population; all study participants had final diagnosis of melanoma
 
Malvehy 2012
Reason for exclusion EXCLUDE not a primary study; review paper
 
Menge 2016
Reason for exclusion EXCLUDE on target population; includes participants with primary possible recurrent
and or previously treated lesions and does not disaggregate results. Also includes
multiple lesions per participant (63 'sites' from 17 participants; unclear how many of
the 39 LM positive on histology had melanoma). 
 
Miller 2011
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Reason for exclusion EXCLUDE on target condition
EXCLUDE on 2x2 data; not an accuracy study
 
Nobre 2011
Reason for exclusion EXCLUDE on sample size; case report
 
Pellacani 2005
Reason for exclusion EXCLUDE if derivation study; uses leave one out
 
Pellacani 2007
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Pellacani 2008
Reason for exclusion EXCLUDE on 2x2 data; no accuracy data provided in the study, looking at correlation
of RCM features to dermoscopy and histology
 
Pellacani 2009
Reason for exclusion EXCLUDE on 2x2 data; Study is testing concordance of terminology used in
RCM...not accuracy. 
 
Pellacani 2012
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Peppelman 2013
Reason for exclusion EXCLUDE on study population; only present data for subtypes of BCC
EXCLUDE on 2x2 data; does not give accuracy data 
 
Peppelman 2015
Reason for exclusion EXCLUDE if derivation study
EXCLUDE on 2x2 data; no data for overall accuracy
 
Peppelman 2016
Reason for exclusion EXCLUDE not a primary study; RCT protocol
 
Puig 2012
Reason for exclusion EXCLUDE on sample size; case report
 
Pupelli 2013
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Reggiani 2015
Reason for exclusion EXCLUDE not a primary study; systematic review
 
Rishpon 2009
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Reason for exclusion EXCLUDE on sample size; only 3 invasive SCC
EXCLUDE if derivation study RCM characteristics for SCC
 
Röwert-Huber 2007
Reason for exclusion EXCLUDE not a primary study; review paper
 
Salerni 2011
Reason for exclusion EXCLUDE on sample size; <5 cases 
 
Scope 2009
Reason for exclusion EXCLUDE on sample size
 
Scope 2014
Reason for exclusion EXCLUDE not a primary study; editorial paper 
 
Segura 2009
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Soyer 2013
Reason for exclusion EXCLUDE not a primary study; comment on a primary study ( Longo 2013 )
 
Stanganelli 2015
Reason for exclusion EXCLUDE on target condition (eligible for melanoma review only)
 
Steiner 1992
Reason for exclusion EXCLUDE on sample size
only two melanomas 
 
Stephens 2013
Reason for exclusion EXCLUDE on sample size
 
Stevenson 2013
Reason for exclusion EXCLUDE not a primary study
systematic review of RCM
 
Tannous 2009
Reason for exclusion EXCLUDE on sample size; only two malignant melanomas 
 
Willard 2011
Reason for exclusion EXCLUDE on sample size; case study
 
Xiong 2016
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Reason for exclusion EXCLUDE not a primary study
systematic review of RCM
 
Yelamos 2016
Reason for exclusion EXCLUDE not a primary study
 
Footnotes
Characteristics of studies awaiting classification 
Borsari 2016
Patient Sampling Not yet assessed
 
Patient characteristics and setting Not yet assessed
 
Index tests Not yet assessed
 
Target condition and reference
standard(s)
Not yet assessed
 
Flow and timing Not yet assessed
 
Comparative Not yet assessed
 
Notes Published October 2016; after search dates
 
Guitera 2016
Patient Sampling Not yet assessed
 
Patient characteristics and setting Not yet assessed
 
Index tests Not yet assessed
 
Target condition and reference
standard(s)
Not yet assessed
 
Flow and timing Not yet assessed
 
Comparative Not yet assessed
 
Notes Published October 2016; after search dates
 
Jain 2017
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Patient Sampling Not yet assessed
 
Patient characteristics and setting Not yet assessed
 
Index tests Not yet assessed
 
Target condition and reference
standard(s)
Not yet assessed
 
Flow and timing Not yet assessed
 
Comparative Not yet assessed
 
Notes Published March 2017; conference abstract only
 
Ludzik 2016
Patient Sampling Not yet assessed
 
Patient characteristics and setting Not yet assessed
 
Index tests Not yet assessed
 
Target condition and reference
standard(s)
Not yet assessed
 
Flow and timing Not yet assessed
 
Comparative Not yet assessed
 
Notes Published September 2016; after search dates
 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of keratinocyte skincancers in adults?
Population: 
 
Adults with lesions suspicious for skin cancer, including:
in participants with any suspicious lesion, where RCM might be used as an alternative to dermoscopy or
to supplement visual inspection alone
in participants with equivocal lesions in whom a clear management decision could not be made following
visual inspection and dermoscopy, where RCM might be used as an addition to visual inspection or
dermoscopy, or both
Index test: Reflectance confocal microscopy (RCM)
Comparator
test: Visual inspection or dermoscopy, or both
Target
condition:
 
Basal cell carcinoma (BCC)
Cutaneous squamous cell carcinoma (cSCC)
Reference
standard: Histology with or without long-term follow-up
#165b Reflectance confocal microscopy for the diagnosis of keratinocyte skin cancers in adults
55 / 119
Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of keratinocyte skincancers in adults?
Action: If accurate, negative results of RCM will stop patients having unnecessary excision of skin lesions; positiveresults could inform the use of nonsurgical management options
Quantity of
evidence Target condition Number of studies Total lesions Total cases
  BCC 10 (11 cohorts) 2037 464
  cSCC 4 (4 cohorts) 834 71
Limitations 
Risk of bias: 
High (4/11) or unclear (3/11) risk for patient selection with exclusion on image quality and use of a case-
control design. Low risk for index test (11/11). High risk from inadequate reference standard (2/11) and
unclear blinding of the reference standard to the RCM result (8/11). Differential verification in 3/11, timing of
tests not mentioned in 7/11 and exclusions due to technical difficulties in 4/11.
Applicability of
evidence to
question:
High (8/11) or unclear (3/11) concern for participants and setting with narrowly defined populations (3/11) or
multiple lesions per patient (5/11). High concern for index test (7/11) with remote RCM interpretation (5/11)
blinded to clinical information (3/11), lack of detail on the diagnostic threshold (2/11) and novice RCM users
(2/11). The studies are dominated by one particularly expert research group (8/11). Little information given
concerning the expertise of the histopathologist.
FINDINGS: 
A total of 10 studies providing data for 11 cohorts of lesions were eligible for inclusion, seven in our target populations of
interest. All seven cohorts reported data for detection of BCC and two reported data for detection of cSCC. The findings
presented are based on results from these seven cohorts. Insufficient data were available to compare RCM with visual
inspection or dermoscopy or to consider the effect of using formally developed algorithms to assist RCM diagnosis. There
was some evidence of melanomas or SCCs being misdiagnosed as BCCs and of higher sensitivity in cohorts using more
experienced observers.
Test: RCM for detection of BCC using any or no algorithm at any threshold in any suspicious lesion 
Datasets (n) Lesions (n) Cases (n) Sensitivity (95% CI) Specificity (95% CI)
4 912 107 76% (95% CI: 45, 92%) 95% (95% CI: 66, 99%)
Numbers in a
cohort of 1000
lesions** 
True 
positives
False
positives
False
negatives
True 
negatives
PPV NPV
At median
prevalence
12.5%
95
(56; 115)
44
(298; 9)
30
(69; 10)
831
(578; 866)
68%
(16; 93)
97%
(89; 99)
At lower
quartile
prevalence
10%
75
(45; 91)
45
(306; 9)
24
(54; 8)
856
(595; 892)
63%
(13; 91)
97%
(92; 99)
At upper
quartile
prevalence
15%
118
(70; 143)
42
(287; 8)
37
(85; 12)
803
(558; 837)
74%
(20; 94)
96%
(87; 99)
Test: RCM for detection of BCC using any or no algorithm at any threshold in equivocal lesions
Datasets (n) Lesions (n) Cases (n) Sensitivity (95% CI) Specificity (95% CI)
3 668 148 94% (79, 98) 85% (72, 92)
Numbers in a
cohort of 1000
lesions** 
True 
positives
False
positives
False
negatives
True 
negatives
PPV NPV
At median
prevalence
15%
141
(119; 147)
128
(238; 68)
9
(32; 3)
723
(612; 782)
53%
(33; 68)
99%
(95; 100)
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Question: What is the diagnostic accuracy of reflectance confocal microscopy for the detection of keratinocyte skincancers in adults?
At lower
quartile
prevalence
11%
100
(84; 104)
134
(250; 72)
6
(22; 2)
760
(644; 822)
43%
(25; 59)
99%
(97; 100)
At upper
quartile
prevalence
29%
276
(232; 288)
106
(198; 56)
18
(62; 6)
600
(508; 650)
72%
(54; 84)
97%
(89; 99)
Test: RCM for detection of cSCC using any or no algorithm 
  Lesions (n) Cases (n) Sensitivity (95% CI) Specificity (95% CI)
In any
suspicious
lesion (n = 1
study)
323 42 74% (58 to 86%) 92% (88 to 95%)
In equivocal
lesions (n = 1
study)
260 13 77% (46 to 95%) 98% (96 to 100%)
Footnotes
** Number of TP, FP, FN, TN have been estimated at the median and interquartile ranges of prevalence, at average
sensitivity and specificity and using the lower and upper limits of the 95% confidence intervals, denoted in brackets (lower
limit; upper limit)
Additional tables 
1 Comparison of RCM with dermoscopy for the detection of BCC
Test StudiesLesions (cases)Sensitivity (95% CI)Specificity (95% CI)
Any suspicious lesion studies (all studies)
RCM 4 912 0.76 (0.45 to 0.92) 0.95 (0.66 to 0.99)
Dermoscopy 0   - -
Any suspicious lesion studies (direct comparisons)
RCM 0   - -
Dermoscopy 0   - -
Equivocal lesion studies (all studies)
RCM 3 668 0.94 (0.79 to 0.98) 0.85 (0.72 to 0.92)
Dermoscopy 1 260 0.85 (0.77 to 0.91) 0.92 (0.87 to 0.96)
Equivocal lesion studies (direct comparisons)
RCM 1 260 0.85 (0.77 to 0.91) 0.94 (0.89 to 0.97)
Dermoscopy 1 260 0.85 (0.77 to 0.91) 0.92 (0.87 to 0.96)
Footnotes
2 Results by observer experience
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Person / image Observer 
experience
Studies (n)Lesions (cases)Pooled sensitivity (95% CI)Pooled specificity
(95% CI)
Detection of BCC
In-person High 3 545 (83) 1.00 (0.96 to 1.00) 0.67 (0.45 to 0.83)
Image High 4 908 (119) 0.86 (0.50 to 0.97) 0.94 (0.86 to 0.98)
Both High 7 1453 (202) 0.98 (0.74 to 1.00) 0.87 (0.71 to 0.95)
In-person Low 2 368 (34) 0.75 (0.53 to 0.88) 0.97 (0.64 to 1.00)
Image Low 2 252 (98) 0.92 (0.82 to 0.97) 0.84 (0.75 to 0.90)
Both Low 4 620 (132) 0.85 (0.69 to 0.93) 0.91 (0.81 to 0.96)
In-person NR 1 122 (56) 0.91 (0.80 to 0.97) 1.00 (0.95 to 1.00)
Image NR 1 260 (114) 0.85 (0.77 to 0.91) 0.94 (0.78 to 0.97)
Both NR 2 382 (170) 0.88 (0.80 to 0.93) 0.98 (0.74 to 1.00)
Detection of cSCC
In-person High 0 0 - -
Image High 2 452 (47) 0.95 (0.06 to 1.00) 0.99 (0.40 to 1.00)
Both High 2 452 (47) 0.95 (0.06 to 1.00) 0.99 (0.40 to 1.00)
In-person Low 1 318 (39) 0.41 (0.26 to 0.58) 0.97 (0.95 to 1.00)
Image Low 0 0 - -
Both Low 1 318 (39) 0.41 (0.26 to 0.58) 0.97 (0.95 to 1.00)
In-person NR 1 122 (11) 0.82 (0.48 to 0.98) 0.96 (0.91 to 0.99)
Image NR 1 260 (13) 0.77 (0.46 to 0.95) 0.98 (0.96 to 1.00)
Both NR 2 382 (24) 0.79 (0.59 to 0.91) 0.98 (0.96 to 0.99)
Detection of any skin cancer (KER)
In-person High 0 0 - -
Image High 3 552 (161) 0.94 (0.70 to 0.99) 0.86 (0.82 to 0.90)
Both High 3 552 (161) 0.94 (0.70 to 0.99) 0.86 (0.82 to 0.90)
In-person Low 2 368 (95) 0.80 (0.71 to 0.87) 0.85 (0.81 to 0.89)
Image Low 1 90 (35) 0.83 (0.66 to 0.93) 0.85 (0.74 to 0.92)
Both Low 3 458 (130) 0.81 (0.73 to 0.87) 0.85 (0.81 to 0.89)
In-person NR 0 0 - -
Image NR 1 260 (140) 0.91 (0.85 to 0.95) 0.80 (0.72 to 0.87)
Both NR 1 260 (140) 0.91 (0.85 to 0.95) 0.80 (0.72 to 0.87)
Footnotes
NR - Not reported
3 Comparison of RCM with dermoscopy for the detection of cSCC
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Test StudiesLesions (cases)Sensitivity (95% CI)Specificity (95% CI)
All lesion studies (all studies)
RCM 1 323 (42) 0.74 (0.58 to 0.86) 0.92 (0.88 to 0.95)
Dermoscopy 0   - -
All lesion studies (direct comparisons)
RCM 0   - -
Dermoscopy 0   - -
Equivocal lesion studies (all studies)
RCM 1 260 (13) 0.77 (0.46 to 0.95) 0.98 (0.96 to 1.00)
Dermoscopy 1 260 (13) 0.77 (0.46 to 0.95) 0.99 (0.96 to 1.00)
Equivocal lesion studies (direct comparisons)
RCM 1 260 (13) 0.77 (0.46 to 0.95) 0.98 (0.96 to 1.00)
Dermoscopy 1 260 (13) 0.77 (0.46 to 0.95) 0.99 (0.96 to 1.00)
Footnotes
4 Comparison of RCM with dermoscopy for the detection of any skin cancer
KER StudiesLesions (cases)Sensitivity (95% CI)Specificity (95% CI)
Any suspicious lesion studies (all studies)
RCM 2 373 (100) 0.85 (0.77 to 0.91) 0.86 (0.82 to 0.98)
Dermoscopy 0   - -
Any suspicious lesion studies (direct comparisons)
RCM 0   - -
Dermoscopy 0   - -
Equivocal lesion studies (all studies)
RCM 2 360 (175) 0.89 (0.82 to 0.94) 0.85 (0.75 to 0.92)
Dermoscopy 1 260 (140) 0.91 (0.86 to 0.95) 0.79 (0.71 to 0.86)
Equivocal lesion studies (direct comparisons)
RCM 1 260 (140) 0.91 (0.85 to 0.95) 0.80 (0.72 to 0.87)
Dermoscopy 1 260 (140) 0.91 (0.86 to 0.95) 0.79 (0.71 to 0.86)
Footnotes
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Test StudiesParticipants
1 BCC - any suspicious lesion 4 912
2 BCC - equivocal lesions 3 668
3 BCC - other lesion populations 4 457
4 BCC - RCM - other - Vivascope 3000 1 54
5 BCC - Dermoscopy - equivocal lesions 1 260
6 BCC - Visual inspection - other lesion populations 1 105
7 SCC - RCM - all comer 1 323
8 SCC - RCM - equivocal 1 260
9 SCC - RCM - other 2 251
10 SCC - Dermoscopy - equivocal 1 260
11 KER - RCM - all comer 2 373
12 KER - RCM - equivocal 2 360
13 KER - RCM - other 1 129
14 KER - Dermoscopy - equivocal 1 260
15 MM2 - RCM - equivocal (non-pigmented) not in melanoma review 1 260
16 BCC - RCM score at >=3 - in person 1 50
17 BCC - RCM score at NR (likely >=3) - in person 2 491
18 BCC - Guitera Two-step alg (significant chars for BCC) - image-based1 356
19 BCC - No algorithm (significant characteristics) - in person 1 54
20 BCC - No algorithm (significant characteristics) - image-based 1 130
21 BCC - No algorithm (selected characteristics) - in person 1 122
22 BCC - No algorithm (selected characteristics) - image-based 1 152
23 BCC - No algorithm (observer diagnosis) - in person 1 318
24 BCC - No algorithm (observer diagnosis) - image-based 4 812
25 BCC - Handheld RCM - No algorithm (significant characteristics) 1 54
28 SCC - No algorithm (selected characteristics) in person 1 122
29 SCC - No algorithm (observer diagnosis) - in person 1 318
30 SCC - No algorithm (observer diagnosis) - image-based 3 712
33 KER - RCM at >=3 - in person 1 50
36 KER - No algorithm (observer diagnosis) - in person 1 318
37 KER - No algorithm (observer diagnosis) - image-based 4 812
38 KER - No algorithm (excise decision) - in person 1 318
39 KER - No algorithm (excise decision) - image-based 2 583
40 BCC - by observer - high - in person 3 545
41 BCC - by observer - high - image-based 4 908
42 BCC - by observer - low - in person 2 368
43 BCC - by observer - low - image-based 2 252
44 BCC - by observer - NR - in person 1 122
45 BCC - by observer - NR - image-based 1 260
47 SCC - by observer - low - in person 1 318
48 SCC - by observer - NR - in person 1 122
49 SCC - by observer - high - image-based 2 452
50 SCC - by observer - NR - image-based 1 260
52 KER - by observer - low - in person 2 368
53 KER - by observer - high - image-based 3 552
54 KER - by observer - low - image-based 1 100
55 KER - by observer - NR - image-based 1 260
Figures
Figure 1
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Caption
Sample photographs of superficial spreading melanoma (left), BCC (centre) and cSCC (right)
Figure 2
Caption
RCM images of normal skin (top) and of lentigo maligna (bottom)
Figure 3
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Caption
Caliber ID Vivascope 1500 with 3000 attachment
Figure 4
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Caption
Current clinical pathway for people with skin lesions
Figure 5
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Caption
PRISMA flow diagram.
Figure 6
Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 7
Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 8 (Analysis 10) 
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Caption
Forest plot of tests: RCM for the detection of BCC in a) any suspicious lesion, b) equivocal lesions, c) other lesion
populations
Figure 9 (Analysis 10) 
Caption
ROC Plot of tests: RCM for the detection of BCC in a) any suspicious lesion, b) equivocal lesions, c) other lesion populations
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Figure 10 (Analysis 11) 
Caption
ROC Plot of tests: RCM versus Dermoscopy in equivocal lesions (Witkowski 2016).
Figure 11 (Analysis 7) 
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Caption
Forest plot of accuracy of RCM to detect BCC by experience (separately for in person and image based studies)
Figure 12 (Analysis 14) 
Caption
Forest plot of tests: RCM for the detection of cSCC in a) any suspicious lesion, b) equivocal lesions, c) other lesion
populations
Figure 13 (Analysis 18) 
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Caption
Forest plot of tests: RCM for the detection of any skin cancer (KER) in a) any suspicious lesion, b) equivocal lesions, c) other
lesion populations
Figure 14 (Analysis 16) 
Caption
ROC plot of tests: RCM for the detection of any skin cancer (KER) for a) correct diagnosis of each malignancy and b)
decision to excise a lesion (image-based evaluations)
Figure 15 (Analysis 17) 
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Caption
ROC plot of tests: RCM for the detection of any skin cancer (KER) for a) correct diagnosis of each malignancy and b)
decision to excise a lesion (in-person evaluations)
Sources of support 
Internal sources
No sources of support provided
External sources
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
NIHR Systematic Review Programme, UK
Feedback 
Appendices 
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Acronym Definition
BCC basal cell carcinoma
BPC between-person comparative (study)
CAD computer-assisted diagnosis
cSCC cutaneous squamous cell carcinoma
DEJ dermo epidermal junction
DTA diagnostic test accuracy
ENT ear, nose, and throat
FP false positive
GP general practitioner
KER any keratinocyte skin cancer
LM lentigo maligna
MEL invasive melanoma or melanoma in situ
MM malignant melanoma
NHS National Health Service
NICE National Institute for Health and Care Excellence
NIHR National Institute for Health Research
NML non melanocytic lesion
OCT optical coherence tomography
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QUADAS Quality Assessment of Diagnostic Accuracy Studies
RCM Reflectance confocal microscopy
RCT randomised controlled trial
RDEB recessive dystrophic epidermolysis bullosa
ROC receiver operating characteristic
SCC squamous cell carcinoma
TN true negative
UK United Kingdom
2 Current content and structure of the Programme Grant
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List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
3 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: Primary /secondary / specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
type of test or algorithm used for test interpretation within each ‘group’ of tests
the nature of and definition of criteria for test positivity
diagnosis in person versus image-based diagnosis
observer experience with the index test
approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
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whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
4 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
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33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
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79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
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7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
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53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
#165b Reflectance confocal microscopy for the diagnosis of keratinocyte skin cancers in adults
91 / 119
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
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42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
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88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
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#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
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#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
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#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
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S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
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S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
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#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: ( MEETING ABSTRACT OR PROCEEDINGS PAPER )
5 Full text inclusion criteria
Criterion Inclusion Exclusion
 
Study design
 
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
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Criterion Inclusion Exclusion
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
6 Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible
to undergo a test should be included in a study, allowing for the intended use of that test within the context of the study. We
considered studies that separately sampled malignant and benign lesions to have used a case-control design; and those that
supplemented a series of suspicious lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types particular lesion sites, or that excluded
lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion
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populations, such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions
to contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We
considered studies that include a high number of lesions in relation to the number of study to be less representative than
studies conducted in a more general population participants (i.e. if the difference between the number of included lesions and
number of included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation, the interpretation of the index test blinded to the result of
the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the
original index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference
standard is known; however, studies using previously acquired images could be particularly susceptible to information bias.
For these studies to be at low risk of bias, we required a clear indication that observers were unaware of the reference
standard diagnosis at time of test interpretation. An item was also added to assess the presence of blinding between
interpretations of different algorithms, however this item was not included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was
not data driven, i.e. was not based on study results. Studies that did not clearly describe the threshold used but that required
clinicians to record a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies
reporting accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported
accuracy for the presence of independently significant lesion characteristics with no separate test set of lesions were
considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would
be in a clinical practice setting, i.e. in person or face-to-face with the patient, and by a single observer as opposed to a
consensus decision or average across multiple observers. Image-based studies were considered to be high concern,
although RCM image interpretations where the observer was also supplied with a clinical or dermoscopic image of the lesion
along with some patient characteristics were considered ‘unclear’.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion
characteristics that were considered to be indicative for skin cancer, particularly where established algorithms or checklists
were not used. Studies were considered of low concern if the threshold used was established in a prior study or sufficient
threshold details were presented to allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test
interpreter as ‘experienced’ or ‘expert’ in RCM to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion
regardless of level of clinical suspicion. In reality, both partial and differential verification bias are likely. Partial verification
bias may occur where histology is the only reference standard used, and only those participants with a certain degree of
suspicion of malignancy based on the result of the index test undergo verification, the others either being excluded from the
study or defined as being disease-negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of
suspicious lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with
benign-appearing lesions but instead follow them up for a period of time to determine whether any malignancy subsequently
develops (these would be false-negatives on the index test). We defined an 'adequate' reference standard as: all disease-
positive individuals having a histological reference standard either at the time of application of the index test or after a period
of clinical follow-up; and at least 80% of disease-negative participants have received a histological diagnosis, with up to 20%
undergoing at least three months' follow-up of benign-appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the
reference standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to
be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology
interpretation. Although inclusion of such clinical information on the histopathology request form is theoretically a form of
incorporation bias, blinded interpretation of the histopathology reference standard is not normal practice, and enforcement of
such conditions would significantly limit the generalisability of the study results. For studies evaluating RCM, this item was
divided into two questions, firstly whether the reference standard was blinded to the index test result (RCM), and secondly
whether it was blinded to the clinical diagnosis. Only the response to the first part (i.e. blinding to RCM) was included in our
overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around
applicability if they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report
histology interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to
each other in time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we
have defined a one-month period as an appropriate interval between application of the index test and the reference standard.
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For studies using clinical follow-up, a minimum three-month follow-up period has been defined as at low risk of bias for
detecting false-negatives.
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were
excluded following recruitment.
Comparative domain
A comparative domain was added to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy.
Items were included to assess the presence blinding of interpretation between tests, and to specify a maximum of one month
interval between application of index tests, as intervals greater than these may be accompanied by changes in tumour
characteristics. As it would not be normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis,
the scoring of this item did not contribute to our overall assessment of risk of bias. We also considered whether both tests
were applied and interpreted in a clinically applicable manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design
clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between
evaluators
Yes if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g. 'difficult to diagnose' lesions, or where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
 
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
A) were the same participant selection criteria used for those
allocated to each test?
B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised
sequence?
C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to
assignment?
For A)
Yes – if same selection criteria were used for each index
test, No – if different selection criteria were used for each
index test, Unclear – if selection criteria per test were not
described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are
described, No – if inadequate randomisation procedures
are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or
'randomised' is insufficient), N/A – if only 1 index test
was evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment
are described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method
of allocation concealment is not described (sufficient
detail to allow a definite judgement is required), N/A – if
only 1 index test was evaluated
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
Could the selection of participants have introduced bias?
For non-comparative and within person-comparative studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
 
For non-comparative and within person-comparative
studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) CONCERNS REGARDING APPLICABILITY
 
1) Are the included participants and chosen study setting
appropriate to answer the review question, i.e. are the study
results generalisable?
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in Risk
of Bias above), but is asking whether the chosen study
participants and setting are appropriate to answer our review
question. Because we are looking to establish test accuracy
in both primary presentation and referred participants, a
study could be appropriate for 1 setting and not for the other,
or it could be unclear as to whether the study can
appropriately answer either question
For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a
skin lesion or B) referred participants, and respond to the
questions in either A) or B) accordingly. If the study gives
insufficient details, please respond Unclear to both parts of
the question
 
A) For studies that will contribute to the analysis of
participants with a primary presentation of a skin lesion (i.e.
test naive)
Yes – if participants included in the study appear to be
generally representative of those who might present in a
usual practice setting
No – if study participants appear to be unrepresentative of
usual practice, e.g. in terms of severity of disease,
demographic features, presence of differential diagnosis or
comorbidity, setting of the study, and previous testing
protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes – if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for
example, we would suggest that this is not representative of
the wider referred population
No – if study participants appear to be unrepresentative of
usual practice, e.g. if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of
disease, demographic features, presence of differential
diagnosis or comorbidity, setting of the study, and previous
testing protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not match the
review question?
If the answer to question 1) or 2) 'Yes':1.
If the answer to question 1) or 2) 'No':2.
If the answer to question 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
INDEX TEST (2) RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes – if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
2) Was the diagnostic threshold at which the test was
considered positive prespecified?
Yes – if threshold was prespecified (i.e. prior to analysing
study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic
threshold was prespecified
3) For within-person comparisons of index tests or testing
strategies (i.e. > 1 index test applied per participant): was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes – if all index tests were described as interpreted
without knowledge of the results of the others
No – if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test have
introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1) and 2) 'Yes':1.
If answers to either questions 1) or 2) 'No':2.
If answers to either questions 1) or 2) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), for any index test and 3)1.
'Yes':
If answers to any 1 of questions 1) or 2) for any index test or2.
3) 'No':
If answers to any 1 of questions 1) or 2) for any index test or3.
3) 'Unclear':
 
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) CONCERN ABOUT APPLICABILITY
 
1) Was the diagnostic threshold to determine presence or
absence of disease established in a previously published
study?
E.g. previously evaluated/established
algorithm/checklist used
lesion characteristics
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid
diagnosis was used or if the diagnostic threshold used was
established in a previously published study
No – if an unfamiliar/new tool to aid diagnosis was used, if
no particular algorithm was used, or if the objective
threshold reported was chosen based on results in the
current study
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold
is described in sufficient detail. This item applies equally to
studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – If the criteria for diagnosis were reported in sufficient
detail to allow replication
No – if the criteria for diagnosis were not reported in
sufficient detail to allow replication
Unclear – If some but not sufficient information on criteria
for diagnosis to allow replication were provided
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
3) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners were
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e. no observer
interpretation
 
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive – 1 or more of the following:
histological confirmation of malignancy following biopsy or
lesion excision
clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to
a histological diagnosis of skin cancer
B) Disease-negative – 1 or more of the following:
histological confirmation of absence of malignancy following
biopsy or lesion excision in at least 80% of disease-negative
participants
clinical follow-up of benign-appearing lesions for a minimum
of 3 months following the index test in up to 20% of disease-
negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of malignancy
underwent 1 of the listed reference standards
No – If a final diagnosis of malignancy for any participant
was reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any participant with a final diagnosis of malignancy or if
the length of clinical follow-up used was not clear or if a
clinical follow-up reference standard was reported in
combination with a participant-based analysis and it was
not possible to determine whether the detection of a
malignant lesion during follow-up is the same lesion that
originally tested negative on the index test
B) Disease-negative
Yes – If at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up
for a minimum of 3 months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 3 months following
the index test or if clinical follow-up period was less than 3
months
Unclear – if the method of final diagnosis was not reported
for any participant with benign or non-melanoma diagnosis
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection or
dermoscopy or both). We will deal with this by not including the
response to this item in the 'Risk of bias' assessment for these
tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached
blinded to the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
If answer to question 1) 'Yes':1.
If answer to question 1) 'No':2.
If answer to question 1) 'Unclear':3.
For all other tests
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
 
For visual inspection/dermoscopy evaluations
Risk is low1.
Risk is high2.
Risk is unclear3.
For all other tests
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) CONCERN ABOUT APPLICABILITY
 
1) Expert opinion (with no histological confirmation) was not
used as a reference standard
'Expert opinion' means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes – if expert opinion was not used as a reference
standard for any participant
No – if expert opinion was used as a reference standard for
any participant
Unclear – if not clearly reported
2) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried
out by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answers to both questions 1), 2), 'Yes':1.
If answers to any 1 of questions 1), 2), 'No':2.
If answers to any 1 of questions 1), 2), 'Unclear':3.
***For teledermatology studies only
If answers to all questions 1) and 3) 'Yes':1.
If answers to questions 1) or 3) 'No':2.
If answers to questions 1) or 3) 'Unclear':3.
Concern is low1.
Concern is high2.
Concern is unclear3.
***For teledermatology studies only
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
A) For histopathological reference standard, was the interval
between index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least 3
months' follow-up following application of index test(s)?
 
A)
Yes – if study reports ≤ 1 month between index and
reference standard
No – if study reports > 1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
B)
Yes – if study reports ≥ 3 months' follow-up
No – if study reports < 3 months' follow-up
Unclear – if study does not report the length of clinical
follow-up
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Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report the interval between
index tests
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
7 Details of RCM algorithms and diagnostic thresholds for diagnosis
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Castro 2015
BCC
 
Guitera 2012
(two step algorithm to id BCC
then MM)
 
Longo 2013
BCC (and MM)
 
Nori 2004 (based on Gonzalez 2002)
BCC
 
Previously-published RCM
criteria assessed (cites Agero
2006; Nori 2004; Guitera 2012)
Selected characteristics chosen;
≥3 RCM criteria present,
including either presence of
§ 'dark silhouettes' or
§ 'bright tumor islands'
Additional criteria assessed:
§ ‘streaming’ polarization of
nuclei in neoplastic aggregates
along the same axis of
orientation;
§ ‘peripheral palisading’ of nuclei
at the tumor islands’ periphery;
§ dark ‘peritumoral clefts’ around
the tumor islands;
§ fibrotic stroma with ‘thickened
collagen bundles’;
§ dilated and tortuous ‘linear
blood vessels’ and ‘coiled blood
vessels’;
§ ‘bright dendritic structures’
within tumor islands; and
§ ‘bright round cells’ in the
stroma.
 
Evaluated 47 RCM features
(referenced to a number of prior
studies) and conducted
multivariate analysis on the
training set of lesions to identify
independently significant
features for MM and for BCC;
assume presence of any one
indicated T+]
Correct id as MM or BCC (based
on independently significant
features as id from training set)
For BCC:
§ Polarized in the honeycomb
§ Linear telangiectasia-like
horizontal vessels
§ Basaloid cord or nodule
§ Epidermal shadow
§ Convoluted glomerular-like
vessels
§ Non-visible papillae
§ Cerebriform nests
§ Disarray of the epidermal layer
 
47 RCM features
recorded;
multivariate
analysis id 4
positive
independent
significant features
for BCC
§ tumour islands
(dark silhouettes or
tightly packed
basaloid islands);
§ cauliflower
architecture;
§ bright filaments
within the tumour
islands; and
§ presence of
bright collagen.
 
Selected 5 criteria from a number of
morphologic characteristics
previously investigated by the same
group, on the basis that they were
‘easily and unambiguously detected
by non-dermatopathologists and a
novice reviewer’
Data presented for >=2, >=3, >=4,
=5 chars present
§ elongated monomorphic basaloid
nuclei;
§ polarization of these nuclei along
the same axis of orientation;
§ prominent inflammatory infiltrate;
§ increased dermal vasculature;
§ pleomorphism of the overlying
epidermis indicative of actinic
changes.
 
Incel 2015
BCC/SCC
 
Results based on ‘observer diagnosis’
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Castro 2015
BCC
 
Guitera 2012
(two step algorithm to id BCC
then MM)
 
Longo 2013
BCC (and MM)
 
Nori 2004 (based on Gonzalez 2002)
BCC
 
Selected characteristics from to
assist correct diagnosis of
different lesion types (cites
Malvehy 2012; Eichert 2010; 
Ahlgrimm-Siess 2010; Röwert-
Huber 2007; Ahlgrimm-Siess
2011)
Characteristics listed for BCC
included:
§ Dark silhouettes in dermis,
§ Bright tumour islands at DEJ
and in the dermis;
§ Cleft-like dark areas;
§ Dendritic cells,
§ Bright round cells,
§ Canalicular vessels.
Characteristics listed for SCC
included: Refractile squam/crust
in stratum corneum and
nucleated cells with dark center
(parakeratotic)cells;
§ Atypical honeycomb pattern,
disarranged pattern at stratum
granulosum layer;
§ Large, round, nucleated cells
at the granular layer
(dyskeratotic cells);
§ Dendritic cells at the granular
layer and small edged papillae
at DEJ;
 
Curchin 2011: applied RCM score: >=3 for suspected melanomas and LM score for
suspected lentigo maligna of the face (Guitera 2010); reports observer correct diagnosis of
BCC; No further details presented
Farnetani 2015: Evaluators completed a ‘pattern description’ (presence/absence of a
number of RCM features) and gave an overall diagnosis of malignant (melanoma or BCC)
or benign
Discriminant analysis also used to id features independently associated with malignancy
(and with MM and BCC separately)
3 more frequently observed in BCC were:
§ basaloid cord–like structures,
§ presence of ulceration,
§ a specific DEJ pattern
Pellacani 2014: presented
Rao 2013: Observers gave diagnosis (MM/BCC/SCC) and excise decision (no further
details)
Witkowski 2016: Report correct diagnosis (MM/BCC/SCC)and excise decision (no further
details)
8 Summary study details by lesion population
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients /
lesions
 
Index tests
(algorithm)
Diagnostic
approach
 
Observer qual.
(n); experience
Additional data
available
 
Reference
standard
Final
diagnoses
 
Exclusions
Any suspicious lesion
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients /
lesions
 
Index tests
(algorithm)
Diagnostic
approach
 
Observer qual.
(n); experience
Additional data
available
 
Reference
standard
Final
diagnoses
 
Exclusions
Any suspicious lesion
 
Curchin
2011
BCC
KER
(MEL)
NC
P-CS
Australia
Secondary
Patient scheduled
for minor excision
42 / 50 VivaScope
1500; Observer
diagnosis (RCM
score for
suspected
melanomas)
In-person
(Single
observer)
 
Observer qual
NR; (n=NR)
Described as
no ce to RCM
analysis after
completing a
RCM analysis
course in
Modena, Italy.
Dermoscopic
and RCM
images were
aligned over the
top of each
other
Histology alone
MM 12; MiS 1;
BCC: 9; cSCC:
6 (includes SK
or AK, or both)
'Benign'
diagnoses: 23
Reported
correct
diagnosis of all
6 SCC or
precursors
(not
disaggregated)
 
Guitera
2012
BCC
(MEL)
WPC
NR-CS
Australia/ Italy
Specialist
clinic/Secondary
Patients with
suspicious lesions,
including those on
face and neck
suspicious for LM,
and requiring
histology to rule
out an epithelial
tumour or an MM;
predominantly
melanocytic or
suspicious for BCC
663 / 710
356 lesions
randomised
to ‘test set’
included
here
VivaScope
1500; No
algorithm
(independently
significant
features for
BCC)
Image-based
(Single
observer)
 
Dermatologist
(n=2);
described as
expert
observers
RCM guided by
dermoscopic
findings but
interpretation
blinded to all
but lesion
location and
patient age
Histology alone
MEL 105;
BCC: 52;
cSCC: 9
BN 132; SN
16; AK 8; 31
benign macule
of the face and
3 DF
BCC: 2MM
and 2 SCC
were FP
 
Pellacani
2014b
(doc)
BCC
(MEL)
NC
P-CS
Italy
Specialist clinic
Patients requesting
a mole check or
with suspicion of
melanoma who
were referred to
PLC clinic.
Documentation
group (doc)
includes lesions
with consistent
clinical or
dermoscopic
criteria, or both, for
melanoma
diagnosis
171 / 184
(1/184 did
not
undergo
RCM)
VivaScope
1500; Observer
diagnosis
(assumed RCM
score for
suspected
melanomas)
In-person
(Single obs)
 
Observer qual
NR (n=1);
diagnosis made
at ‘confocal unit’
RCM reader
was aware that
lesions were
dermoscopically
atypical but
blinded to ‘RCM
documentation’
or ‘RCM
consultation’
Histology alone
(documentation
group)
MM 13; MiS 9;
BCC: 19; 1 mel
mets;
BN 121; SN 8;
SK or other
keratotic 7;
other benign 5
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients /
lesions
 
Index tests
(algorithm)
Diagnostic
approach
 
Observer qual.
(n); experience
Additional data
available
 
Reference
standard
Final
diagnoses
 
Exclusions
Any suspicious lesion
 
Rao 2013
BCC
SCC
KER
(MEL)
NC
NR-CS
US
Secondary
All lesions
removed for
cosmetic or
medical reasons
that were imaged
using a confocal
scanning
microscope
NR / 334
Reader 1
(novice)
evaluated
318
lesions;
Reader 2
(expert)
evaluated
323
lesions;
284 were
examined
by both
readers
VivaScope
1500; No
algorithm
(correct dx of
each
malignancy;
overall observer
diagnosis of
malignancy)
Image-based
(Single
observer)
 
Observer qual
NR (n=2);
Reader 1 had 1
year RCM
experience at
the start of the
study; Reader 2
had > 9 years’
experience with
RCM.
Diagnosis was
based on the
dermoscopic
image and
confocal
microscopy
evaluation
Histology alone
MM 8;
Melanoma (in
situ); 1; BCC:
27; cSCC: 42
BN 176; SK 22;
AK 24; 23
other
BCC: 4 SCC
were FP
SCC: 9 BCCs
picked up as
SCCs were
considered TN
as per
Methods
Equivocal lesion studies
Farnetani
2015
BCC
(MEL)
NC
R-CS
Italy
Secondary
Diagnostically
equivocal lesions
excised due to
clinical or
dermoscopic
suspicion of
melanoma, where
a specific clinical
and dermoscopic
diagnosis could not
be rendered with
certainty
NR / 100 VivaScope
1500; No
algorithm
(observer dx -
pattern
description and
diagnostic
judgment)
Image-based
(Single
observer)
 
Dermatologist
(n=9); 6
experienced
(>=3 years
RCM
experience) and
3 ‘recent’ RCM
users.
Experienced
reader
randomly
selected for
primary
analysis.
Dermoscopic
image provided;
no additional
clinical
information (eg,
age and
melanoma or
lesion history)
 
Histology alone
MEL 20; BCC:
15
SK 7; BN 55;
AK 3
BCC: 14 MM
FP
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients /
lesions
 
Index tests
(algorithm)
Diagnostic
approach
 
Observer qual.
(n); experience
Additional data
available
 
Reference
standard
Final
diagnoses
 
Exclusions
Any suspicious lesion
 
Pellacani
2014a
(cons)
BCC
(MEL)
NC
P-CS
Italy
Specialist clinic
Patients requesting
a mole check or
with suspicion of
melanoma who
were referred to
PLC clinic.
Consultation group
(cons) includes
lesions requiring
an outcome
decision
from RCM (dx
could not be
reached on clinical
or dermoscopic
criteria, or both)
252 / 309
1/308 did
not
undergo
RCM
VivaScope
1500; Observer
diagnosis
(assumed RCM
score for
suspected
melanomas)
In-person
(Single
observer)
 
Observer qual
NR (n=1);
diagnosis made
at ‘confocal unit’
RCM reader
was aware that
lesions were
dermoscopically
atypical but
blinded to ‘RCM
documentation’
or ‘RCM
consultation’
Histology plus
FU (cons
group);
227/308
referred for
sequential
digital FU; 28
later excised
MM 2; MiS 4;
BCC: 19; BN
71; SN 5;
benign NML 8;
199 benign on
FU
 
Witkowski
2016
BCC
SCC
MM
WPC-tests
R-CS
Italy
Secondary
Clinically equivocal
‘pink’ cutaneous
lesions with absent
pigmentation or
containing less
than 10% pigment
and absence of
pigment network.
NR / 260 VivaScope
1500; No
algorithm
(correct dx of
each
malignancy)
Dermoscopy
Image-based
(Single
observer)
 
Dermatologist
(assumed; n=2,
1 dermoscopy 1
RCM);
experience NR
No additional
information
provided
 
Histology alone
MEL 12; BCC:
114; cSCC: 13;
1 syringoid
eccrine
carcinoma
Benign
keratotic 25;
BN 47; SN 6;
DF 18; other
benign 24
BCC: 1 SCC
FP
Other lesion populations
Castro
2015
BCC
WPC
NR-CS
Brazil and USA
Specialist clinic
Patients with one
or more skin
lesions deemed
suspicious for BCC
based on clinical
and dermoscopic
examination.
NR/54  
Vivascope 1500
Vs
Vivascope 3000
(No algorithm;
>= 3
characteristics
present)
Unclear if
image-based;
consensus of 2
 
Dermatologist
(n=1);
experienced
with RCM
examination
and supervised
by skin cancer
expert
Clinical,
dermoscopic
and RCM
imaging
performed by
same
dermatologist
 
Histology
BCC: 45;
'Benign'
diagnoses: 9
38 of original
92 lesions
excluded as
only
accessible to
Vivascope
3000 (mostly
facial).
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Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion criteria No.
patients /
lesions
 
Index tests
(algorithm)
Diagnostic
approach
 
Observer qual.
(n); experience
Additional data
available
 
Reference
standard
Final
diagnoses
 
Exclusions
Any suspicious lesion
 
Incel
2015
BCC
SCC
NC
P-CS
Turkey
Secondary
Patients with
nonpigmented
suspected tumoral
lesions or
proliferative skin
lesions and with a
vascular structure
on dermoscopic
examination
114/122  
Vivascope 3000
(No algorithm;
selected
characteristics;
correct dx of
BCC/SCC)
Unclear if
image-based;
unclear if single
observer)
Observer qual
NR (n=NR);
states “First 60
lesions
subjected to
blinded
evaluation by 2
observers”, no
further details
provided
Histology
BCC: 56;
cSCC: 9
KA 3; SK 11;
AK 8; BD 7;
and 22 other
benign
nonpigmented
tumours
BCC: All SCCs
considered
test negative
Longo
2013
BCC
SCC
KER
(MEL)
NC
R-CS
Italy
Specialist
clinic/Secondary
Clinically nodular
lesions (defined as
cutaneous
palpable/superficial
seated lesions and
not subcutaneous
ones) that
underwent excision
140/140  
Vivascope 1500
(NR but
assumed to be
used; correct
diagnosis of
BCC/SCC)
Image-based
(Single
observer)
 
Dermatologist
(n=1); 5 years’
experience in
RCM
Blinded to
dermoscopy
Histology
NM 23; BCC:
28; cSCC: 6;
Other
malignant: 9
mel mets
SK 14; BN 32
including 7
SN); 5
vascular; 6
other benign
Non evaluable
and non
specific results
excluded
(n=11);
including 1
BCC and 1
SCC
Nori 2004
BCC
WPC
CCS
US and Spain
Secondary/Private
clinic
Biopsy confirmed
BCC and
convenience
sample of non-
BCC with 'range of
common
diagnoses'
145/152
105 had VI
diagnosis
Vivascope 1000
(No algorithm;
selected
characteristics;
>= 3 present)
VI (clinical
photographs;
high/medium/low
probability BCC)
Image-based
(Single
observer)
 
Observer qual
NR (n=1);
'Novice
confocal
reviewer'
Blinded
interpretation
 
Histology or
expert
diagnosis;
15/65 benign
had clinical dx
BCC: 83 ( 58 in
VI analysis);
cSCC: 4
'Benign'
diagnoses: 65
BCC: Cannot
disaggregate
SCC result
(n=4) from rest
of D- group
NR – not reported; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma in situ (or lentigo maligna);
BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrheic keratosis;
SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF – dermatofibroma; FU – follow-up; R
–retrospective; P – prospective; CS – case series; CCS – case control study; WPC – within person comparison (of tests); BPC
– between person comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; Cons - consensus
diagnosis; exp - experience; VI - visual inspection; dx - diagnosis
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